  
 
INTERMITTENT HYPOXIA AND CAFFEINE IN INFANTS BORN 
PRETERM (ICAF)  
Protocol Number: R01HD089289 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED] 
Principal Investigator s:  
Carl E. Hunt, MD  
Eric Eichenwald, MD     
Sponsor: NIH  
Funded by: NIH: 1R01HD089289 -  01A1  
Version Number:  4. 2 
 09 September 2021 
  
  
 
Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................ 4 
1 PROTOCOL SUMMARY  .............................................................................................................................. 4 
1.1 Synopsis  ............................................................................................................................................... 4 
1.2 Study Schema ..................................................................................................................................... 8 
1.3 Schedule of Activities (SoA)  .............................................................................................................. 9 
2 INTRODUCTION  ......................................................................................................................................... 10 
2.1 Study Rationale  .................................................................................................................................  10 
2.2 Background  ........................................................................................................................................ 10 
2.2.1  Known Potent ial Risks  .................................................................................................. 12 
2.2.2  Known Potential Benefits  ............................................................................................. 13 
2.2.3  Assessment of Potential Risks and Benefits  ............................................................. 14 
3 OBJECTIVES AND ENDPOINTS  ............................................................................................................. 14 
4 STUD Y DESIGN  .......................................................................................................................................... 17 
4.1 Overall Design  ................................................................................................................................... 17 
4.2 Scientific Rationale for Study Design  ............................................................................................. 17 
4.3 Justification for Dose  ........................................................................................................................ 18 
4.4 End of Study Definition  ..................................................................................................................... 18 
5 STUD Y POPULATION  ................................................................................................................................ 18 
5.1 Inclusion Criteria  ............................................................................................................................... 18 
5.2 Exclusion Criteria  .............................................................................................................................. 19 
5.3 Lifest yle Considerations  ................................................................................................................... 19 
5.4 Screen Failures  .................................................................................................................................  19 
5.5 Strategies for Recruitment and Retention  ..................................................................................... 19 
6 STUDY INTERVENTION ............................................................................................................................ 20 
6.1 Study In tervention(s) Administration  .............................................................................................. 20 
6.1.1  Study Intervention Description  .................................................................................... 20 
6.1.2  Dosing and Administration  ........................................................................................... 20 
6.2 Preparation/Handling/Storage/Accountability  ............................................................................... 21 
6.2.1  Acquisition and accountability  ..................................................................................... 21 
6.2.2  Dose Preparation, and Labeling  .................................................................................. 21 
6.2.3  Product Storage and Accountability  ........................................................................... 22 
6.3 Measures to Minimize Bias: Randomization and Blinding .......................................................... 23 
6.4 Study Intervention Compliance ....................................................................................................... 23 
6.5 Concomitant Therapy  ....................................................................................................................... 24 
6.5.1  Rescue Medicine  ........................................................................................................... 24 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  25 
7.1 Discontinuation of Study Intervention  ............................................................................................ 25 
7.2 Participant Discontinuation/Withdrawal  from the Study  .............................................................. 25 
7.3 Lost to Follow -Up .............................................................................................................................. 25 
8 STUDY ASSESSMENTS AND PROCEDURES  ..................................................................................... 27 
8.1 Efficacy Assessments  ...................................................................................................................... 27 
8.1.1  Oxygen Saturation ......................................................................................................... 27 
8.1.2  Inflammarory Biomarkers  ............................................................................................. 27 
8.1.3  Quantitative MRI Structural, Microstructural and Metabolic Biomarkers of Acute Brain Injury
 28 
8.1.4  Salivary caffeine levels  .................................................................................................  28 
8.1.5  Brief Infant Sleep Questionnaire (BISQ)  .................................................................... 29 
8.2 Safety and Other Assessments  ...................................................................................................... 29 
  
8.2.1  Telephone assessment of status at home .................................................................  29 
8.3 Adverse Events and Serious Adverse Events  .............................................................................. 29 
8.3.1  Definition of Adverse Events (AE)  .............................................................................. 29 
8.3.2  Definition of Serious Adverse Events (SAE)  ............................................................. 29 
8.3.3  Classification of an Adverse Event  ............................................................................. 30 
8.3.4  Time period and frequency for event assessment and follow -up ........................... 31 
8.3.5  Adverse Event Reporting  ............................................................................................. 31 
8.3.6  Serious Adverse Event Reporting  ............................................................................... 32 
8.3.7  Reporting Events to Participants  ................................................................................. 32 
8.3.8  Events of Special Interest  ............................................................................................ 32 
8.3.9  Reporting of Pregnancy  ................................................................................................ 33 
8.4 Unanticipated Problems  ................................................................................................................... 33 
8.4.1  Definition of Unanticipated Problems (UP)  ................................................................ 33 
8.4.2  Unanticipated Problem Reporting  ............................................................................... 33 
9 STATISTICAL CONSIDERATIONS .......................................................................................................... 34 
9.1 Statistical Hypotheses  ...................................................................................................................... 34 
9.2 Sample Size Determination  ............................................................................................................. 34 
9.3 Populations for Analyses  ................................................................................................................. 35 
9.4 Statistical Analyses  ........................................................................................................................... 35 
9.4.1  General Approach  ......................................................................................................... 35 
9.4.2  Analysis of the Primary Efficacy Endpoints  ............................................................... 35 
9.4.3  Safety Analyses  ............................................................................................................. 38 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............................. 38 
10.1  Regulatory, Ethical, and Study Oversight Considerations  .......................................................... 38 
10.1.1  Informed Consent Process  .......................................................................................... 38 
10.1.2  Study Discontinuation and Closure ............................................................................. 39 
10.1.3  Confidentiality and Privacy  ........................................................................................... 39 
10.1.4  Future Use of Stored Specimens and Data  ............................................................... 40 
10.1.5  Key Roles and Study Governance  .............................................................................. 40 
10.1.6  Safety Oversight  ............................................................................................................ 41 
10.1.7  Clinical Monitoring  ......................................................................................................... 41 
10.1.8  Quality Assurance and Quality Control  ...................................................................... 42 
10.1.9  Data Handling and Record Keeping  ........................................................................... 42 
10.1.10  Protocol Deviations  ....................................................................................................... 42 
10.1.11  Publication and Data Sharing Policy  .......................................................................... 42 
10.1.12  Conflict of Interest Policy  .............................................................................................. 43 
10.2  Additional Considerations  ................................................................................................................ 43 
10.3  Abbreviations  ..................................................................................................................................... 44 
10.4  Protocol Amendment History  .......................................................................................................... 45 
8.1.3 Quantitative MRI Structural, Microstructural and Metabolic Biomarkers of Acute Brain Injury  ... 56 
REFERENCES  ......................................................................................................................................................... 57 
 
  
  Page 4 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 STATEMENT OF COMPLIA NCE  
The trial will be carried out in accordance with International Conference on Harmoniz ation  Good 
Clinical Practice ( ICH GCP) and the following :  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 
46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 
All National Institutes of Health ( NIH)-funded investigators a nd clinical trial site staff who are 
responsible for the conduct, management, or oversight of this study  have completed Human 
Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study.  In addition, a ll changes to the consent form will be IRB -approved; a 
determination will be made regarding whether  a new consent needs to be obtained from 
participants  who provided consent , using a previously approved consent form . 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  Intermittent Hypoxia and Caffeine in Infants Born Preterm (ICAF)  
Study Des cription : 
 
  
 
   
 
   Our proposal will address the critical question: is persisting intermittent 
hypoxia ( IH) in preterm infants associated with biochemical, structural, or 
functional injury, and is this injury attenuated with extended caffeine 
treatment? We will study the effects of caffeine on IH  in 220 preterm infants 
born at ≤30 w eeks + 6 days gestation. Infants who are currently being 
treated with routine caffeine, and who meet eligibility criteria, will be 
enrolled between 32 weeks + 0 days and 36 weeks + 6  days PMA .  At 
enrollment, i nfants will be started on continuous pulse oximeter recording 
of O 2 saturation and heart rate .  If, based on standard clinical criteria, the 
last dose of routine caffeine is given on or before the day the infant is 36 
weeks + 5 days PMA,   then , ideally,  on the day following, but no later than 
the third calendar day following,  their last dose of routine caffeine 
treatment, infants  will be randomized (110/group) to extended caffeine 
treatment or placebo . Randomized infants should  begin recei ving study 
drug (i.e. 5 mg/kg/ of caffeine base, or equal volume of placebo ) on the day 
of randomization , but no later than  the third calendar day following the last 
dose of routine caffeine .  Prior to 36 w eeks + 0 days PMA, study drug will 
be given once daily (i.e. 5mg/kg/day) and beginning at 36 w eeks  + 0 days  
PMA , study drug will be given twice daily (i.e. 10 mg/kg/day) .  The last dose 
of study drug will be given at 42  weeks  + 6 days  PMA. Pulse oximeter 
  Page 5 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
  
 recordings will cont inue either until hospital discharge  or for 1 week  after 
discontinuing study drug  depending on whether the infant was recruited 
at a study  site at which home oximetry recording is being performed.  Two 
caffeine levels will be obtained, the 1st at one week a fter beginning study 
drug, but no later than 14 days post -first-dose of study drug. T he 2nd 
targeted at  40 weeks + 0 days PMA , but no earlier than 39 weeks+ 0 days 
and no later than the last day of study drug, whether in hospital or at home . 
Inflammatory biomarkers will be measured at s tudy enrollment and again 
at 38 weeks + 0 days PMA  plus or minus 3 days , or within 2 calendar days 
prior to hospital discharge, whichever comes first. At study sites recruiting 
into the MRI part of the study, q uantitative MR I/MRS should  be obtained 
between  study enrollment and 3 calendar days after starting study drug and 
again at a target date of 43 week s + 0 days, but no later than 46  weeks + 6 
days PMA . 
Objectives:  
 Primary Objective  1: Compare the extent of IH  exposure , from 
randomization through  42 w eeks + 6 days  PMA (within each gestational 
week and overall) , in infants randomized to extended caffeine treatment to  
infants assigned to receive  placebo.    
Primary Objective 2:  Compare changes in a panel of inflammation -related  
cytokines and chemokines , from enrollment to the target age of 38 w eeks 
+ 0 days PMA, in infants randomized to extended caffeine treatment  to 
infants assigned to receive placebo .  
Primary Objective 3: Compare changes in quantitative MRI structural, 
microstructural and metabolic biomarkers of acute injury , from enrollment 
to 43 -46 weeks PMA, in infants randomized to extended caffeine treatment  
to infants assigned to receive placebo .  
Secondary Objective 1: Examine the association between salivary caffeine 
concentrations and IH  outcomes at the one week post randomization and  
40 weeks + 0 days PMA  assessments.  
Secondary Objective 2: Determine whether caffeine effects on changes in 
inflammatory or MRI biomarkers from baseline to follow -up are mediated 
by caffeine -related reduced IH.  
  
  Page 6 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Endpoint s: Primary:  
• Extent of IH  as measured by seconds below 90% saturation per 24 
hours  of recorded oximetry data within each week PMA, and overall     
• Plasma concentration  changes in inflammatory biomarkers 
between baseline and 38 weeks + 0 days PMA  
• MRI changes in microstructural measures between baseline and 
end of study (between 43 weeks + 0 days and 46 weeks + 6 days 
PMA).   
Secondary  
• #IH events per 24 hours of recorded oximetry data , # sec < 80% 
saturation per 24 hours of recorded oximetry data , nadir saturation 
during events, and the duration of events and area under of curve 
during events below 90% and 80% threshold saturation   
• Changes in inflammatory biomarkers and MRI measures of regional 
tissue volume  between baseline and end of study  in relation to IH 
measures  
Study Population:  Sample size: 220 infants, 110 caffeine and 110 placebo -treated  
Gender: Male and female  
Age: Enrollment at PMA 32 w eeks + 0 days -  36 w eeks + 6 days  
Demographic Group:  Infants born at ≤30 w eeks + 6 days gestation  
General Health Status:  Clinically stable, on caffeine treatment and expected 
to receive last dose of routine caffeine treatment no later than 36 weeks + 
5 days PMA  
Geographic locat ion: NICU or step down unit at a  participating hospital, with 
final weeks at home following NIC U discharge   
Phase:  Not applicable  
 
Description of Sites /Facilities  Enrolling 
Participants:   
Neonatal Intensive Care Units (NICU) in  hospitals  in metropolitan areas in 
the U.S. While inpatient the research will take place in the hospital . Once 
discharged , if the subject has been enrolled at a site performing MRIs,  the 
patient will return to specified outpatient locations for performance of the 
follow -up MRI.  At the end of the study,  study termination procedures will 
be performed in a manner convenient for the family, and may be performed in person or remotely, and if applicable  may be performed at the time of 
an MRI .  
   
Description of Study 
Intervention:  Enrolled infants will be randomized to receive caffeine or equal volume 
placebo. The c affeine base dose will be 5 mg/kg once daily when the infant 
is at age 35 wee ks + 6 days PMA or less. W hen the infant is at 36 weeks + 0 
days PMA or more the caffeine base dose will be 5 mg/kg twice daily , based 
on the expected increased rate  of caffeine metabolism that occurs as 
infants age.   
Study Duration:  Enrollment  is scheduled to  start  in December , 2018 and will continue at 
least through May of 202 2, with completion of follow -up and data analyses 
thereafter . 
  
  Page 7 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Participant Duration:  The maximum time between study enrollment to study completion for an 
individual participant  would be 15 weeks if enrollment was as early as 32 
weeks + 0 days and the final visit was at the latest time permitted at 46 
weeks + 6 days.   Since enrollment is permitted as late as 36 weeks + 6  days, 
and the final study visit may occur as early as 43 weeks + 6 days, a 
participant may complete the full study in as few as 7 weeks .    
 Hospital discharge most commonly occurs between 34 and 40 weeks PMA, and we expect most infant s to have roughly half their time in the s tudy as 
in-patient and half as outpatient, though this may be vary widely.   
 
 
 
The end of study procedures  include: return of the oximeter  (if applicable) , 
salivary  sample and any unused study drug.  As noted above, these 
procedures will be done at the convenience o f the family, and although a 
face -to-visit is preferred,  all items  may  be shipped back if , for any reason, 
the parents prefer not to travel to the site.  
   
 
 
  
  Page 8 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 1.2 STUDY SCHEMA  
Our goal is to randomize 220 infants born at a gestational age of 30 weeks + 6 days or  less, who get their 
last dose of routine caffeine treatment between 32 weeks + 0 days and 36 weeks + 5 days PMA , to receive 
either extended caffeine treatment or placebo  to 42 weeks + 6 days .  As illustrated  below, all NICU 
admissions of infants bo rn at 30 weeks + 6 days or less will be noted in the screening log.  Formal screening 
for eligibility will begin at 32 weeks + 0 days, with enrollment once infants meet all eligibility requirements, 
and the infant is at 36 weeks + 6 days  or less PMA.  Betw een enrollment and randomization, baseline data 
will be collected.  Randomization will be performed , ideally,  on the day following, but no later than  the 
third calendar day following, the last dose of routine caffeine, as long as randomization and dosing is by 
36 weeks + 6 days PMA.   Outcome measures will include oxygen saturation recordings, plasma biomarkers 
and brain MRI.  

  Page 9 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 1.3 SCHEDULE OF ACTIVITI ES (SOA)  
1.  Study drug (caffeine base 5 mg/kg QD or placebo, weight adjusted weekly while in hospital) begins 1 day after last day of rou tine 
caffeine, but no later than the 3rd calendar day after last dose of routine caffeine.   Dose is increased to 5 mg/kg BID at 3 6 + 0; finally, 
the last dose of study drug is at 42 + 6.  Note that initial dose will be BID if enrolled at 36 + 0 or later.  
2. 2nd caffeine level targeted at 40 + 0, (no earlier than 39 + 0 and no later than last day of study drug), whether in hospital or at home.  
3. 1st biomarker blood sample should be obtained as close as possible to the day of randomization. Whenever possible, this bl ood sample 
should be timed with a clinically required blood draw. To facilitate obtaining this sample at the time of a clinical blood dr aw, this 
sample may be obtained at any time after consent, but no later than the 2nd calendar day after the first dose of study drug.  The 2nd 
sample is to be obtained at 38 + 0 (+ or –  3 days) or within 2 calendar days prior to hospital discharge, whichever comes first.  
4. 1st MRI/MRS is done in hospital sometime between enrollment and 3 calendar days after starting study drug.  2nd MRI/MRS is targeted 
at 43 + 0 but should be no later than 46 + 6.  MRI visit may be combined with the end of study visit. MRI/MRS scans will only  be 
performed for subjects enrolled at sites participating in the MRI/MRS portion of the study.  
5. Include s documentation of tracking information, and parent training including: use of oximeter, drug administration, use of drug 
administration log, salivary sample collection, communication expectations and follow -up plans.  
6. Weekly phone calls from study staff to parent(s) begin 1 - 3 days after hospital discharge and continue through end of study follow up 
visit.  A phone follow -up form will be completed to collect clinical data, adverse events, and document family questions.  
7. Sleep Assessment (BISQ) done over the phone with parent at 42 weeks.  
8. The e nd of study visit , which may be done remotely,  is targeted for 43 + 6 days, or one week after the last dose of study drug, 
whichever comes first, but should be completed no later than 46 + 6.  Study staff will collect the study drug log, used bottles, unused 
drug, study oximeter, and frozen salivary s ample. Items may be shipped back if the parents opt for a remote visit.  
9. Collection of concomitant medications and adverse event monitoring and reporting are continuous throughout study.  
10. Home- oximetry will only be performed for subjects enrolled at sites participating in the home -oximetry portion of the study.  Study 
Procedures  ≤30 w eeks + 6 
days thru 36 
weeks + 6 
days  32 wee ks 
+ 0 days 
thru 36 
weeks + 6  
days  Target: 1 
day post 
last 
routine 
caffeine 
dose  (but 
window of 
up to 3 
calendar 
days 
allowed)  1 week on 
study drug  
(up to 14 
days post 
1st dose)  36 weeks  
+ 0 days  
PMA  Hospital 
Discharge  40 weeks 
+ 0 days 
PMA  42 week s  
+ 6 days 
PMA  43 week s       
+ 6 Days PMA  
Screening  X                 
Informed 
Consent    X               
Enrollment    X               
Baseline Data 
Collection    X               
Pulse oximetry 
recording    X10 
  
Randomization      X             
Once daily 
study drug      X1           
Twice daily 
study drug          X1   
Drug log     X   
Saliva for 
caffeine level        X     X2      
Biomarker 
blood sample    X3     X3       
MRI/MRS    X4             X4 
Pre-discharge 
checklist            X5       
Weekly parent 
phone contact            X6   
Infant sleep Q               X7   
End of study 
visit                 X8 
Concomitant 
medications    X9 
Adverse Event    X9 
  Page 10 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
  
 
2  INTRODUCTION  
 
2.1 STUDY R ATIONALE   
   Caffeine treatment for apnea of prematurity and related intermittent hypoxia (IH)  is almost universal, 
with treatment most commonly discontinued at 33 -35 w eeks PM A.   However, IH  continues to occur in 
infants after routine discontinuation of caffeine, and persists after hospital discharge. This IH is not 
apparent clinically and accurate detection requires continuous high resolution pulse oximetry recordings . 
Studies confirm that the IH occurring during spontaneous breathing after stopping routine caffeine is a 
manifestation of immature breathing control. It is unknown if this persistent IH results in acute injury, 
and in particular if extending the duration o f caffeine treatment attenuates or prevents this acute 
injury.  This study will address 3 critical questions: 1) will extending caffeine treatment from 32-35 to 42 
weeks PMA reduce extent of IH, 2) is persisting IH  associated with biochemical, structural, o r functional 
indicators of acute injury, and 3)  does caffeine treatment continued to 42 wee ks PMA attenuate this acute 
injury? This study has the potential to (1) identify early brain injury mediated by IH  and mitigated by 
caffeine at appropriate dosing, and (2) help inform optimum strategies for later definitive neurodevelopmental assessments based on nature of the acute brain injury. This study thus has high 
potential to justify future neurodevelopmental outcome studies that will further improve outcomes of 
infants born preterm, change clinical practice, and have significant public health benefit.  
2.2 BACKGROUND   
Acute morbidities can contribute to adverse neurodevelopment outcomes in preterm infants born at ≤30 
weeks gestation, but neural damage occurring after resolution of acute morbidities may be more subtle 
and related to cycles of inflammation and repair in the developing brain. One possible contributor to these 
more subtle injuries is intermittent hypoxia (IH) , defined as repetitive cycles of hypoxia and re -
oxygenation, which occur commonly in convalesc ing premature infants. Caffeine treatment can improve 
both motor and cognitive neurodevelopmental outcome in premature infants, especially at higher doses, 
but m echanisms are unclear .1-8 The Caffeine for Apnea of Prematurity (CAP)  Trial in infants born preterm 
at <1250 g reported 1)  shorter duration of positive pressure ventilation and reduced rate of 
bronchopulmonary dysplasia (BPD) in infants treated with caffeine during the early postnatal w eeks prior 
to 34 -35 w eeks postmenstrual age (PMA), 2) improved motor function and reduced rates of 
developmental coordination disorder at 5 years, and 3) diffusion changes by MRI consistent with 
improved white matter microstructural development.7,9,10,11 Although potential mechanisms for this 
caffeine effect were not studied in these reports, a recent study of very preterm infants in postnatal weeks 
1-10 showed for the first time a direct link between IH and motor, cognitive and language impairment  
at 18 months corrected age (adjusted risk gradient p<0.005).12 Notably, the greatest risk gradient was at 
postnatal ages 9 -10 w eeks, consistent with a contributory role of later IH  present after stopping routine 
caffeine treatment. T hese data emphasize the potential importance of recurrent episodes of IH , as 
convalescing infants approach term -equivalent age, on later cognitive, language and motor impairments.    
   Studies confirm that IH during the early postnatal w eeks of life in ve ry preterm infants may be due to 
other  mechanisms, including ineffective ventilation or other acute morbidities. However, IH in 
  Page 11 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 spontaneously breathing convalescing infants is due to ventilatory immaturity with associated respiratory 
pauses or brief apneas, and has a characteristic pattern of brief desaturation from a normoxic baseline  
followed by reoxygenation and return to normox ia.13-18 Our study will assess IH  only during spontaneous 
breathing in infants after resolution of acute morbidities or need for supplemental O 2, and approaching 
term -equivalent age, a time when IH  has been shown by us and others to be the consequence of i mmature 
breath ing regulation.  
   IH during spontaneous breathing related to ventilatory immaturity requires continuous high resolution 
pulse oximetry recordings for detection, and consists of brief, repetitive cycles of O 2 desaturation from a 
normoxic base line, followed by return to baseline saturations. These repetitive cycles of reoxygenation 
following each IH  episode are pro -inflammatory and cause oxidative stress, free radical production, and 
release of pro -inflammatory cytokines.19,20 Studies show incr eased levels of inflammatory biomarkers in 
animal models of IH-associated obstructive sleep apnea ( OSA ) and in human subjects with OSA.19,21- 25 
Although inflammatory biomarkers may be elevated in the first 2 -3 postnatal weeks in very preterm 
infants who de velop BPD and neurodevelopmental sequelae, it is unknown if later IH during spontaneous 
breathing in convalescing preterm infants is associated with inflammation or other biochemical, 
structural or metabolic acute injury or adverse consequences.26-31 
   We  have reported that clinically unrecognized IH  events are still common after discontinuing routine 
caffeine treatment, typically at 34 -35 weeks PMA.18 Except for 1 study, however, the potential adverse 
consequences  of IH have not been investigated in human  infants.12,18,32 -34 In obstructive sleep apnea, 
however,  even modest amounts of chronic IH have been associated with significant neurocognitive 
morbidity.23,24  Worrisome evidence from animal models also shows that IH has significant and long lasting 
effects on multiple physiological control mechanisms20-24,35 -40 and neurological outcomes.41-43 We 
hypothesize that persistent IH in spontaneously  breathing preterm infants after stopping routine caffeine 
treatment is associated with acute adverse consequences.            
   The relationship between IH , adenosine, caffeine and brain development is complex and not fully 
understood. At clinically effective doses, caffeine exerts effects in the brain by blocking adenosine (Ado ) 
A1 and A2A receptors, resulting in respiratory stimulation and increased alertness, vigilance and 
arousal.44-60 Ado A1 receptor activation contributes to hypoxia -induced reduction in cerebral myelination 
and ventriculomegaly. Caffeine treatment attenuate s the effects of hypoxia, presumably through 
blockade of Ado A1 receptors.45,58,59 It is thus reasonable to hypothesize that similar mechanisms may be 
active in the human preterm infant. Caffeine may thus be neuroprotective  through two major 
mechanisms: 1)  reducing incidence and severity of IH due to its respiratory stimulatory effects, and 2) 
reducing pre - and immature oligodendrocyte  injury.  
   Brain development progresses through a highly programmed series of events.61-64 Myelination in the 
cerebral hemispheres begins to accelerate at ~30 -32 w eeks and continues to term and beyond, and 
disturbances in these late gestation developmental processes often result in failure of normal brain 
growth, abnormal cortical organization,  impaired myelination, and connectivity, commonly observed in 
surviving preterm infants.64-75 Persisting IH thus has even greater potential for later neurodevelopmental 
  Page 12 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 disability than the IH  associated with obstructive sleep apnea.23,24,76- 84 Since IH can be attenuated with 
extended caffeine,  persisting IH may thus be a m odifiable cause  of a previously unrecognized 
additional risk for disabilitie s assoc iated with preterm birth.7,18,41,42,45,55,73,85 -88   
   In s ummary , the period from  32-35 to 42 weeks PMA is a critical time for brain development, and is 
also a time when significant IH during spontaneous breathing is present, but the adverse effects of this 
IH are unknown. As the first  step in understanding acute injury from IH, we address a fundamental and 
critically important question with high potential public health benefit: does continued caffeine treatment 
after receiving the last dose of  routine caffeine between 32 weeks + 0 days  PMA and 36 weeks and 5 
days PMA reduce ext ent of IH and attenuate indicators of acute injury at 43 -44 w eeks PMA? We will 
assess injury in 4 domains: biochemical (inflammation), structural (MRI), functional and metabolic (MRS). 
Our proposed study thus has the potential to have major impacts on clin ical practice: 1)  how clinicians 
assess and interpret IH,  and 2) duration of pharmacological t reatment with caffeine.  This will be the first 
study in human infants to assess the effects of continuing caffeine treatment in attenuating acute injury 
indicato rs associated with IH .  
2.2.1  KNOWN  POTENTIAL RISKS  
• Study drug:  Caffeine  is one of the most frequently used medications in the NICU for infants born very 
preterm . At the time of enrollment,  infants will be tolerating routine caffeine treatment without any 
adverse clinical effects .  However, known potential side effects of caffeine , would  include:  
o Transient decreased weight gain  
o Tachycardia  
o Gastrointestinal symptoms , including feeding intolerance  
o Jitteriness    
o Hypertension  
Each of these side effects would be  expected in fewer than 5% of participants . 
• Pulse oximeter recordings : Pulse oximetry is routinely used in the NICU and sometimes also 
indicated for home use. The study oximeter will be in addition to the comparable oximeter 
routinely used clinically. We will follow routine clinical routines for frequent site relocation of the 
oximeter sensor s (probes), to decrease the risk of  significant skin irritation.  
• Blood  sampling for inflammatory biomarkers :  There will be 2 blood samples obtained, one at 
enrollment and the 2nd prior to NICU discharge, and the blood volume for each sampling will be <1 ml. Whenever possible, these blood samples will be obtained as part of a clinically indicated 
routine heel stick or venipuncture, thus decreasing  the need to cause infant discomfort beyond 
that required for routine clinical management.  
• Brain MRI : All MRIs performed for this study will be done without sedation, th us eliminating the most 
important  potential risk beyond that associated with a clinically -indicated brain MRI .  However , the 
time required for each study MRI will be more than that required for a routine brain MRI .   
• Salivary samples : The 2 salivary caffein e samples for each subject will be obtained using a 
commercially available salivary collection kit identical to that used in our recent pilot study. These salivary collections are easily obtained and have not been associated with any infant discomfort or parental concern.   
• Loss of confidentiality  is also a potential risk. However, all demographic and clinical information will 
be entered in a secure password -protected database accessible only to the research staff at that 
  Page 13 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 clinical site and the data coordinating center (DCC) at Boston University Medical Center. Clinical site 
research staff will enter data via web access. Identifiers that have been collected will be stored 
separately from research data. The data will be in a separate locked/password protected database 
linked only by a subject ID number. Identifiers collected for the purpose of performing follow -up will 
be stored in a separate database that will be destroyed after the study is completed. The data will be 
split as it is loaded; personal identifiers (names, addresses, telephone numbers) will be entered into the tracking database along with a unique numeric identifier, and other data (excluding the participants' names and address) will be stored in the analytic database. It will be possible to link information in these two databases only through a coded numeric identifier; it will not be possible to identify individual participants in the analytic database. The separation of names and addresses from personal data adds an important level of se curity and helps to assure that participant confidentiality 
will be maintained. Follow -up data will be processed in a similar manner. The analytic database will 
contain no identifiers and will be the exclusive source for all data analyses performed at the DCC.     
Database files will be stored at the DCC on network servers located in a data center at the Slone Epidemiology Center at Boston University.   Slone Epidemiology Center data center is a separate 
secure room monitored by key access.   Activity on the  Slone network and servers is monitored by a 
University security team.   In addition, access to the Slone network is restricted by specific Virtual 
Private Network group access and router access control lists.   Servers are protected by software 
firewalls and  enterprise antivirus software. Administrators to the servers are limited to a core group 
of individuals who oversee server health and security. Network access to the servers is protected by requiring a user to login to an Active Directory system using the  assigned username and Kerberos 
password.   Access to directories and files are restricted by user membership to network security 
groups.   Network security group membership is granted only if a user is affiliated with a research study 
or group.   When a user  is not affiliated with any research study or group, access is denied and 
removed. Backup data is taken at regular intervals.   This backup data is encrypted and stored in a 
secure off- site facility for three years.   Any request for file restoration is exam ined, monitored, and 
documented.   After three years, backup data is verified and certified for destruction.  Any websites 
used by Slone for data collection are protected with SSL protocols —commonly referred to 
HTTPS.   These protocols provide encrypted commu nication and secure identification of web servers 
using certificates.   Certificates are signed by trusted certificate authority.  
• Recurrence of A pnea -related symptoms in placebo -treated subjects : We have not observed any 
recurrent apnea -related symptoms in preliminary studies after stopping routine caffeine .18,90  
However, if a subject  has apnea -related clinical symptoms after stopping routine caffeine and starting 
study drug, nasal CPAP or nasal cannula may be used as needed at the discretion of the clinica l team.  
After the last dose of s tudy drug at 42 w eeks + 6 days PMA, pulse oximeter recordings will be 
continued for 1 additional w eek, to 43 weeks + 6 days PMA , for those participants enrolled at sites at 
which home oximetry is included in the study . No significant alarms have occurred after stopping 
extended caffeine treatment in our pilot studies, and none are anticipated in this clinical trial since at 
this PMA the extent of IH  no longer differs from healthy term infants .15,16  However,  the oximeter  
alarms can be activated for this final study week if deemed necessary by the clinical site investigator.   
 
2.2.2  KNOWN POTENTIAL BENE FITS  
Direct Potential Benefits :  
• Infants randomized to receive extended caffeine treatment may benefit directly by having less 
intermittent hypoxia and hence less inflammation and improved brain MRI findings  
  Page 14 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 • Placebo -treated infants will benefit from the additional support and information provided by 
research staff, and will have the potential for benefit from information obtained from the MRI 
evaluations, which would not have been done absent enrollment in this study. Except for the inflammatory biomarkers and brain MRIs, placebo -treated enrollees are equivalent to “usual 
care” clinical practice in NICUs today.  
 
General Future Pot ential Benefits : 
• This study  will fill several major gaps in our current knowledge: 1) The impact on 
neurodevelopmental outcome of the frequency and severity of IH  in the NICU and at home until 
43 weeks PMA, assessed by continuous pulse oximeter recordings of oxygen saturation and heart 
rate, 2) the frequency and severity of IH in preterm infants receiving caffeine vs. placebo while in 
the NICU, 3) the frequency and severity of IH persisting at home after discharge  (for participants 
receiving home oximetry) , and 4) the efficacy of continuing caffeine treatment until 4 2 weeks  + 6 
days  PMA with regard to reducing IH  and improving neurodevelopment.   
• Infants randomized to caffeine may benefit from improved neurodevelopmental outcome related 
to attenuated IH  during the period of exposure to study drug.  
2.2.3  ASSESSMENT OF POTENT IAL RISKS AND BENEFITS  
• The risk: benefit  ratio is favorable  
• Extending caffeine treatment to 42 w eeks + 6 days PMA has the potential of improving brain 
structure and function as determined by MRI , and improv ing neurodevelopmental outcomes.   
• Infants randomized to placebo will be receiving what is currently the standard of care when their 
last routine caffeine dose is  between 32 weeks + 0 days  PMA and 36 weeks and 5 days PMA .  
• The potential risks are primarily related to b lood sampling and the brain MRIs. As discussed above, 
however, the blood samples will be obtained as a part of clinically indicated blood sampling, and 
the MRIs will be performed without sedation.  
• In summary, the potential benefits exceed the potential risks of participation in this study, and 
there are no increased risks if randomized to receive placebo since placebo infants will otherwise 
be receiving the same clinical care as comparable infants not enrolled in this study .     
     
 
 
 
     
3 OBJECTIVES AND ENDPO INTS  
 
  Page 15 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
Primary    
Primary Objective 1:  Compare the 
extent of IH  exposure, from 
randomization through 42 weeks 
+ 6 days PMA (within each 
gestational week and overall), in 
infants randomized to extended 
caffeine treatment to infants 
assigned to receive placebo.  
Primary Objective 2:  Compare 
changes in a panel of 
inflamma tion-related  cytokines 
and chemokines, from enrollment 
to the target age of 38 weeks + 0 days PMA, in infants randomized 
to extended caffeine treatment to 
infants assigned to receive placebo .  
 
Primary Objective 3 : Compare 
changes in quantitative MRI structural, microstructural and metabolic biomarkers of acute injury, from enrollment to 43 -46 
weeks PMA, in infants 
randomized to extended caffeine 
treatment to infants assigned to 
receive placebo .  
  # of sec of IH <90% at each PMA 
week  
  
 
 
 
 
 
Change in plasma concentration 
of each inflammatory biomarker from baseline to 38 
weeks PMA.  
  
 
     Difference between 
neuroimaging  measures at 
baseline and at 43 -46 weeks 
PMA , including diffusion tensor 
imaging (DTI) and proton 
magnetic resonance spectroscopy  (MRS) . # of sec of IH <90% the most 
representative measure to quantitate extent of IH  
    
 
 
Measuring  biomarker 
concentrations at 38 w eeks 
will be a sufficient interval for 
changes since baseline, and 
will be the interval during 
which differences in extent of IH will be maximal.  
    
Quantitative MRI is a sensitive modality for assessing structural, biochemical, and 
functional changes 
consequent to IH and extent 
of improvement with extended caffeine treatment. Assessing at study end will provide maximal time for adverse MRI changes consequent to IH since 
starting study drug .  
Secondary    
Secondary Objective 1: Examine 
the association between salivary 
caffeine concentrations and IH 
outcomes at the one week post 
randomization and 40 weeks + 0 days PMA assessments.  
Secondary Objective 2: 
Determine whether changes , from 
baseline to  follow -up, in Extent of IH  (# of sec <90%) 
paired with saliva caffeine level 
during PMA week of oximetry 
recording.  
 
 
Change in plasma concentration 
for each inflammatory  
# of sec of IH  <90% is the 
most representative measure 
of extent of  IH during the 
week corresponding in time 
to the caffeine level.  
  
See above    
  Page 16 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
inflammatory or MRI biomarkers 
are mediated by caffeine -related 
reduced IH. biomarker, from baselin e to 38 
weeks PMA, in relation to IH 
measures.  
Change in each MRI parameter, 
from baseline  to 43 -46 weeks 
PMA  in relation to IH measures . 
 
  
  Page 17 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 4 STUDY DESIGN  
4.1 OVERALL  DESIGN  
HYPOTHESES : 
Hypothesis 1 : Caffeine will reduce extent of IH  compared to placebo, and this caffeine effect will persist 
to 42 w eeks PMA.    
Hypothesis 2 : Extended caffeine treatment will be associated with less acute inflammation at 37 -38 w eeks 
compared to placebo, and these effects will be mediated by attenuated IH. 
Hypothesis 3 : Qua ntitative MRI analyses in the active caffeine group,  compare d to the placebo  group,  will 
be associated with  1) greater white matter microstructural organization, 2)  improved neuronal 
metabolism, and 3)  greater regional brain volume, and that these effects will be mediated by attenuated 
IH. 
TYPE/DESIGN  OF TRIAL : 
Randomized, placebo -controlled, double -blinded clinical trial   
METHODS TO BE USED TO MINIMIZE BIAS : 
All clinical team personnel and all research staff (except research pharmacist) will remain blinded to study 
group until study completion. Caffeine and equ al volume placebo will be prepared by research pharmacist 
and will be equivalent in color and consistency. The protocol has been designed such that there should be 
no need to break the code for any individual subject.  
NUMBER OF STUDY GROUPS/ARM  & STUDY INTERVENTION DURATION : 
Infants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, caffeine  base  (Arm 1) and placebo (Arm 
2). Infants from multiple births will be cluster randomized.  The duration of the intervention will be from 
randomization between 32 weeks + 0 days PMA and 36  weeks + 6 days PMA through  42 w eeks  + 6 days  
PMA, the age at which extent of IH no longer differs from healthy infants born at term.  
 
MULTI -SITE STUDY : 
There will be enrollment at multiple  hospitals across the U.S.  
NAME OF STUDY INTERVENTION :  
Caffeine versus placebo  
 
INTERIM ANALYSIS :  None planned  
STRATIFICATION : 
A site -stratified randomly -permuted blocked randomization design will be used to ensure balance at each 
site. To ensure balance by gestational age at birth, randomization will also be stratified into 2 birth 
gestational age categories: 1)  <28 w eeks 2) 28 weeks  + 0 days through  30 w eeks + 6 days . The 
randomization scheme will be developed by the DCC using specialized software, and clinical sites w ill be 
provided appropriate enrollment logs and randomization procedures from the research pharmacy.  
 
SUB-STUDIES :  No ancillary studies planned at this time  
 
4.2 SCIENTIFIC R ATIONALE FOR S TUDY DESIGN  
  Page 18 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Our pilot studies have demonstrated that IH associated with immature breathing pattern in infants born 
preterm can be attenuated with caffeine. It is unknown, however, whether persisting IH  after stopping 
routine caffeine  treatment in the NICU, which may  only evident with continuing high resolution pulse 
oximetry, results in any long -term injury. The results in the group randomized to extended caffeine 
treatment (Arm 1) will be compared to placebo (Arm 2) to determine if extended caffeine treatment is 
superior to placebo in attenuating or eliminating  the adverse effects of persisting IH on inflammation and 
brain MRI structural, microstructural, and metabolic markers of injury.  
 
4.3 JUSTIFICATION FOR DO SE 
Infants will be started on oral caffeine base at 5 mg/kg/day or equivalent volume of placebo. At 36 weeks 
+ 0 days PMA, study d rug dose will be increased to 5 mg/kg BID (total daily dose 1 0 mg/kg) or equivalent 
volume of placebo. The dose will be weight -adjusted weekly until NICU discharge.  The starting dose and 
dose escalation at 36 w eeks + 0 days PMA  reflect increasing clearance rates  that have been established in 
pilot studies  as being appropriate to achieve caffeine levels within the most likely therapeutic range .  All 
subjects will be on enteral  medi cations when enrolled.  
4.4 END OF S TUDY DEFINITION  
 
Each subject will be considered to have completed the study after the planned pulse oximeter  reco rding 
data is completed  and inflammatory biomarker samples are provided, and  if applicable,  has compl eted 
the outpatient brain MRI between  43 weeks + 0 days and 46 weeks + 6 days PMA, as  shown in the 
Schedule of Activities (S OA), Section 1. 3. 
 
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
INCLUSION CRITERIA : 
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
 
1. Male and female infants born preterm at ≤30 weeks  + 6 days  postmenstrual  age 
2. Current treatment with routine caffeine .  Note infants will meet this inclusion criteria through  the 
third calendar day follow ing receiving their most recent routine caffeine dose.   
3. PMA 32 weeks + 0 days -  36 weeks  + 6 days  
4. Anticipated last dose of routine caffeine will be by 36 weeks + 5 days  
5. At least 12 hours of breathing room air  with no ventilatory support other than on room air nasal  
air flow therapy regardless of flow rate, or on room air  and receiving nasal CPAP , and relapse 
not anticipated.  
6. Able to tolerate enteral medications   
7. It is feasible to administer the first dose of study drug no later than 36 weeks + 6 days P MA 
  
 
  
  Page 19 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
  
5.2 EXCLUSION CRITERIA  
EXCLUSION CRITERIA : 
1. Intraventricular hemorrhage Grade III -IV or cystic periventricular leukomalacia  
2. Current or prior treatment for seizures  
3. Current or prior treatment for cardiac arrhythmias  
4. Known renal or hepatic dysfunction that in  the opinion of the investigator would have a clinically 
relevant impact on caffeine metabolism  
5. Major malformation, inborn error of metabolism, chromosomal abnormality  
6. Presence of a condition for which survival to discharge unlikely  
7. Social, mental health, logistical or other issues that, in the opinion of the investigator, would 
impact the ability of the family to complete the study.  
 
 
 
 
5.3 LIFESTYLE CONSIDERAT IONS  
• Parents and clinical care providers will be asked to avoid exposure to caffeine for subjects . 
• Open label treatment with a methylxanthine will be documented.   
• There will be no restrictions on maternal diet even if breast feeding.  
5.4 SCREEN FAILURES  
• Screened and potentially eligible i nfants for enrollment will be screen failures if they reach 36  
weeks + 6 days PMA and are still receiving  routine caffeine or, for whatever reason, cannot be 
enrolled by 36  weeks + 6 days  PMA . 
• Enrolled infants will be screen failures , and will not be randomized, if they do not continue to 
meet  eligibility criteria at the ti me that routine caffeine treatment is being discontinued .  
• Analysis will be by “intention to treat,” and all randomized subjects will remain included in their  
Arm for analysis.    
5.5 STRATEGIES FOR RECRU ITMENT AND RETENTION  
RECRUITMENT : 
• Potential enrollees will all be inpatients in the NICU at one of the participating hospitals .  
All inpatients in the NICU born at ≤30 wee ks + 6 days postmenstrual age will be captured in the 
screening log, and beginning at 32  weeks + 0 days PMA, if they are being treated with routine 
caffeine , will be screened for potential eligibility.  Screening w ill be discontinued whenever 
infants meet a specified exclusion criterion for enrollment or if they reach 36 weeks + 6 days 
PMA wi thout meeting all inclusion criteria. It is estimated based on pilot studies that 30 -50% of 
all screened infants will meet 1 or more exclusion criteria or fail to meet inclusion criteria.   If an 
infant is a transfer from another facility at ≤36+6, they WIL L be added to the screening log.  If 
they are a transfer from another facility at ≥37+0, they WILL NOT be added to the screening log.  
• The families of infants who are meeting enrollment criteria will be approached by study staff 
regarding possible enrollment.   
 
  Page 20 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 RETENTION : 
• As infants are approaching the time of discharge staff will utilize the pre -discharge  checklist to:  
o Obtain detailed tracking information that provide s information regarding where the 
infant will be cared for post -discharge and multiple methods to contact key family 
members  
o Provide and document comprehensive training of families regarding use of the oxygen 
saturation recorder  
o Provide and document traini ng of families regarding giving study drug to their infant and 
using the home drug log  
o Provide and document training of families regarding obtaining and storing the saliva 
sample for caffeine levels  
o Provide and document training of families related to study expectations for future 
communication (i.e. telephone contacts)  and study visits  for the MRI, if necessary, and 
the end of study visit   
• Following discharge  families will be contacted within 1 –  3 days after discharge and then at least 
wee kly to support families in performing study procedures including drug administration, use of 
oximeter  (if applicable) , and ascertain any concerns about these procedures or the clinical status 
of the infant, including the occurrence of adverse events.  
• The p arents of each subject will receive gift cards for a total of $100, at completion of their 
participation in the study . The purpose is to defray travel expenses for the return visit, if 
applicable,  and for baby supplies, indicating our appreciation for their support of the collective 
protocol requirements.  
 
6 STUDY INTERVENTION  
  
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
• The intervention for this study is the extended treatment of infants with caffeine , for evaluation 
of the efficacy of extended caffeine in ameliorating persisting IH and its adverse consequences 
including inflammation and brain MRI structural and functional injury.  Caffeine is a standard 
treatment  in preterm infants in the NICU, but  currently is commonly discontinued between 32 
and 36 weeks PMA.  T he FDA has granted an IND Exemption for the extended treatment with 
caffeine to 42 weeks + 6 days .  
 
 
6.1.2  DOSING AND ADMINISTR ATION  
• The dose of caffeine  base  will be the same caffeine dose per kg as determined in our recent pilot 
study, both the QD starting dose and the BID dose at 36 w eeks + 0 days PMA to adjust for 
increasing rates of metabolism.  
• The caffeine doses used have been shown in our pilot study to be s ufficient to achieve and 
maintain effective systemic concentrations for significant attenuation of IH 
• The equal volume placebo will be identical in appearance to the caffeine  
  Page 21 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 • Due to the relatively long half -life of caffeine, timing of doses may have some variance to best 
accommodate routine care and feeding schedules. The time of the 1st dose will be approximately 
24 hours after the last routine clinical dose, and the subsequen t QD doses will be given at the 
same approximate time each day, as consistent with daily care schedules. Timing of the BID doses 
starting at 36 w eeks + 0 days PMA will be determined as consistent with daily care schedules, and 
will then be continued at the  same times every day.  After discharge, t iming of the doses may 
initially be modified to be most consistent with home care schedules, and then repeated at the same approximate time(s)  each day.  
• All study drug will be given prior to a feeding.    
• Study drug will b e continued from the 1st dose, which will be given sometime between 32 weeks 
+ 0 days and 36 weeks + 6 days PMA, through  the last scheduled dose at 42  weeks + 6 day s PMA.  
• Study drug will be administered by clinical care personnel in the same man ner as for routine 
caffeine use. Clinical care and/or research staff will teach parents how to administer so that administration at home will be comparable to that in the NICU.  
• For home use, families will be instructed how to draw up the proper dose from t he study drug 
vials supplied by research staff.  
• Missed QD doses will be given as soon as possible after the missed dose , but that dose will be 
eliminated (and details recorded) if missed for more than  12 hours. For BID doses, missed doses 
will be given as soon as possible after the missed dose, but that dose will be eliminated (and details recorded) if missed for more than 6 hours.  
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.1  ACQUISITION AND ACCO UNTABILITY  
Each clinical research site is responsible for procuring the required supplies needed to prepare blinded 
doses for both inpatient and outpatient doses.  See Pharmacy Manual for specific compounding 
ingredients and instructions.  
• Instructions will be provided to the parents/caregivers to administer the blinded oral doses just 
prior to the morning feeding and just prior to a late afternoon or early evening feed (breast or 
bottle). A diary will be provided for recording all administered dose s.  
• All used bottles and unused study solution will be returned to t he research pharmacy  (IDS)  at 
study end.  
6.2.2  DOSE PREPARATION , AND LABELING  
Inpatient Doses:   Caffeine base or Placebo  
Caffeine base :  IDS pharmacies will prepare a bulk oral solution containing caffeine base (anhydrous) 10 
mg/mL, according to the instructions in the Pharmacy Manual .  A bulk solution can be prepared 
individually for a patient or can be used for multiple patients (preferred) who are assigned/randomized 
to receive active treatment.  
A 24 hour supply is prepared from the bulk solution and dispensed in a suitable -sized unit -dose, oral 
syringe. All oral syringes prepared and administered in the inpatient setting are to be labeled in a blinded 
fashion, using specific departmental procedures for labeling of blinded syringes and reflecting blinded 
  Page 22 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 study drug information on the medication administration record (e.g. eMAR).  All syringes must be labeled 
as “For Investigational Use Only” (or alternative site specific verbiage to identify a stud y medication).  
Syringes can be prepared as long as 4 days prior to administration (BUD 4 days) and should be stored at 
room temperature . 
Example:  Caffeine base 10 mg/1 mL or Placebo; Caffeine base 10 mg or placebo (1 mL)        
 
Placebo :  Research pharmac ies will prepare a bulk oral solution according to instructions in the pharmacy 
manual .  A bulk solution can be prepared individually for a patient or can be used for multiple patients 
(preferred) who are assigned/randomized to receive placebo treatment.  
A 24 hour supply is prepared from the bulk solution and dispensed in a suitable -sized unit -dose, oral 
syringe. All oral syringes prepared and administered in the inpatient setting are to be labeled in a blinded 
fashion, using specific departmental procedures for labeling of blinded syringes and reflecting blinded 
study drug information on a medication administration record (e.g. eMAR). All syringes must be labeled 
as “For Investigational Use Only” (or alternative site specific verbiage to identify a study m edication). 
Syringes can be prepared as long as 4 days prior to administration (BUD 4 days) and should be stored at 
room temperature . 
Example:  Caffeine base 10 mg/1 mL or Placebo; Caffeine base 10 mg or placebo (1 mL)  
 
Outpatient Doses:  
Doses intended for  outpatient administration, starting at time of discharge and continuing until 42 weeks 
+ 6 days PMA, are prepared by the IDS pharmacy at each clinical site and issued as a bulk solution 
containing a sufficient quantity of either the active drug (caffeine base) or placebo to last until 42 weeks 
+ 6 days (BUD 9 0 days) .   
6.2.3  PRODUCT STORAGE AND ACCOUNTABILITY  
IDS pharmacies are temperature controlled and have access limited to pharmacy personnel only.  
Compounding and accountability records are maintained by the  IDS pharmacy to reflect drug preparation 
and dispensing for patients receiving both the active and placebo solutions, prepared for both inpatient 
and outpatient treatment. All supplies used to prepare both the active and placebo oral solutions are to 
be s tored in the IDS/research pharmacy, in accordance with temperature parameters indicated on the 
product label.  
Sites may use/develop their own accountability forms; specific information to be documented on the drug accountability record includes: patient in itials, patient study ID number, individual dose (mg per mL), lot 
number and beyond use date of the prepared solution.  For outpatient dosing, the quantity dispensed 
(mLs), the dose and the dispensing date must also be recorded.  The use of an electronic r ecord (e.g., 
Vestigo) is acceptable as long as the required information is captured, including patient -returned 
medication.  
  Page 23 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Any remaining doses of study drug not administered at home are to be returned by the family member 
during the end -of-study outpatien t visit if applicable, or sent back , and eventually returned to the IDS 
pharmacy for on -site destruction following reconciliation and accountability of the unused doses.  Used 
bottles are to be returned to the IDS pharmacy; if remaining solution is present , it is to be measured and 
recorded as a return.  Empty bottles are to be recorded as zero mL.  Once the information for the returned 
bottle has been recorded, the solution and bottle can be disposed of as non -hazardous pharmaceutical 
waste, according to institutional procedures.  
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION  AND BLINDING  
Randomization:  
• Ideally o ne day  following , but up to the third calendar day  following the last routine caffeine 
treatment dose , enroll ed infants will be randomized in a 1:1 ratio to 1  of 2 treatment arms, 
caffeine base or placebo .  
• Infants from multiple births will be cluster randomized.   
• A site -stratified randomly -permuted blocked randomization design will be used to ensure balance 
at each site.  
• To ensure balance by gestational age at birth, randomization will also be stratified into 2 birth 
gestational age categories: 1 ) <28 weeks and 2)  28 weeks + 0 days through 30 weeks  + 6 days 
gestation .  
• A randomization scheme will be developed by the DCC using specialized software, and clinical 
sites will be provided appropriate enrollment logs and blinded randomization procedures.  
 
Blinding :  
• Treatment assignments will be blinded until study completion for all study personnel, except for 
the clinical site research pharmacy dispensing study drug.  
• The study pulse oximeter will not have visual displays or alarms for respiration or heart rate  
activated during the study period ending at 43 weeks + 6 days . The IH which is the focus of study 
typically does not result in overt apnea or b radycardia , and therefore we do not anticipate a need 
for unblinding based on oximeter results  
• Any r equests for unbli nding will be adjudicated by one of the study Principal Investigators , and 
can only be authorized by them.  
• Two s alivary caffeine concentrations are being obtained from  all subjects, but the results of the 
caffeine concentrations will be blinded until all infants have completed the study protocol.  
• Potential caffeine side effects, such as mild tachycardia, irritability or feeding difficulties are frequent  in both caffeine -treated non-treated infants. If such concerns arise, however, at the 
discretion of the clinical care team, study drug may be held for the days necessary , and noted in 
study records , but  would generally not be a reason to request  unblinding.  
• If apnea -related symptoms requiring treatment occur after starting study drug, the clinical care 
team may institute treatment as needed un til cessation of these symptoms, and similarly, this 
also should not require unblinding.   
6.4 STUDY INTERVENTION  COMPLIANCE  
• Approximately the 1st half of study duration will be in the later weeks of the NICU admission. 
Durin g this time, compliance with protocol requirements will be closely monitored by research 
staff and documented in the database.  
  Page 24 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 • To maximize compliance with study protocol during the several weeks a t home, f amilies will be 
instructed in all aspects of protocol adherence while in the NICU, and reinforced just prior to 
discharge.  
• Once discharged, research staff will contact each family within the first  2-3 days home to address 
parental concerns  or questions, and encourage compliance with study procedures.  Staff will re -
contact each family at least weekly thereafter to support families and encourage full home 
compliance with protocol requirements.  
• Two salivary caffeine concentrations will be  obtained in all subjects .  Although results  will not be 
available until the end of the study, the results will be useful in analyses to assess adherence to the administration of study drug, and understand the relationship between caffeine 
concentrations  and study safety and efficacy outcomes . 
6.5 CONCO MITANT THERAPY  
Uniform treatment guidelines for routine treatment caffeine have been developed for the study and agreed to by sites.  The Clinical Guidelines for Routine Caffeine Use in NICU (Prior to enrollment in ICAF) 
include: For infants with birth weight < 1250 grams, initiate caffeine treatment within the first 3 days after birth in all infants .  If on CPAP only:  initiate caffeine treatment within the first 24 hours . If approaching 
extubation in first 3 days after birth prior to any caffeine treat ment , initiate caffeine treatment 6 to 8 
hours prior to extubation.  For infants with birth weight ≥1250 grams, if on CPAP or on no respiratory 
support, initiate caffeine treatment if the infant experiences >6 apnea episodes requiring stimulation . If 
the infant requires mechanical ventilation, consider starting caffeine treatment prior to extubation.  The 
initial caffeine dose is a 20  mg/kg bolus dose of caffeine citrate (or equivalent caffeine base) followed by 
5-10 mg/kg/day maintenance dose, beginning 24  hours after the loading dose.  Levels are not required to 
monitor for dosage adjustment.  Stop routine caffeine treatment once the infant is free of clinically 
significant episodes of apnea for 5 -7 days off of any positive pressure (CPAP or NC > 1L) or at 34 weeks 
PMA , whichever comes first .  If the maintenance dose is less than 5 mg/kg, infants may be allowed to 
“outgrow” their dose of caffeine  and the dose should be stopped as noted above ( i.e. no clinically 
significant episode for 5 -7 days off any positi ve pressure (CPAP or NC > 1L)  or 34 weeks PMA, whichever 
comes first .) Following randomization, open label caffeine use is discouraged, however, there are no 
prohibited therapies and sites will manage all partici pants based on their best clinical judgment , with 
guidance as needed by the an ICAF Principal Investigator.   
 
6.5.1  RESCUE MEDICINE  
As noted above, rescue therapy with open -label caffeine therapy is discouraged.   Recurrent apnea -
related symptoms have not occurred in preliminary studies after stopping routine caffeine. 18,90 
However, in the event that an infant has apnea -related clinical symptoms after stopping routine caffeine 
and star ting study drug, study drug should  be continued , and if judged to be needed by the clinical team , 
nasal CPAP or nasal c annula is the preferred additional therapy .   If the clinical team ultimately decides 
that open -label caffeine must be used, we suggest the following:  1) Hold study drug; 2) begin open -
label maintenance caffeine citrate at 5 -10 mg/kg/day on the same day; 3) as soon as open -label caffeine 
is no longer deemed necessary, stop open -label caffeine and restart study drug at the next regularly 
scheduled time for study drug; 4) there should be n o need to unblind the treatment group, since  
published studies have suggested that it is safe to give the suggested dose of  open -label caffeine  to 
either treatment group .3 If the attending physician thinks unblinding may be needed they should contact 
the clinical site principal investigators . 
  Page 25 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Pulse oximeter recordings will continue through hospital discharge, or at home through  1 week 
following discontinuation of study drug , for infants recruited at sites participating in home oximeter 
recording . The PMA at which study drug is scheduled to end is well after the clinical team judged it safe 
to stop routine caffeine treatment and at a PMA at which prior studies have shown that the extent of IH  
no longer differs from healthy infants born at term.  Howev er, for sites continuing oximeter recordings 
at home , the oximeter alarms may be activated for this final study week if deemed necessary by the 
clinical site principal investigators.  
 
7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT 
DISCONTINUATION /WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
The clinical site principal investigators  may discontinue the participant ’s activity without the participant ’s 
consent if either  of these criteria are met:  
• A participant  consistently  fails to comply with study procedures  
• A participant ’s safety or health may be compromised by further participation  
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE S TUDY  
Each study participant  may withdraw consent at any time during the study without penalty. In the event 
a participant  is discontinued and thus no longer  receiving the study drug, the participant  will be asked to 
continue with follow -up assessment as described below, and not considered withdrawn from the study. 
If the participant  refuses further follow -up, then  the participant  will be considered to be withdrawn. 
Counseling about the participant 's health will be provided if the participant  decides to discontinue 
participation in the study. Medical advice regarding what is in the best interest of the participant  will be 
provided.  
All data c ollected up to the time of withdrawal will be reported. The End of Study eCRF will be completed, 
with the reason for withdrawal specified.  
7.3 LOST TO F OLLOW- UP 
• A participant will be considered lost to follow -up if he or she fails t o return for the end-of-study 
visit between  43 weeks + 0 days and 46 weeks and 6 days PMA and is unable to be contacted by 
the study site staff  to (1) reschedule the final visit for the brain MRI  (if applicable) to be completed 
by 46 weeks + 6 days , and (2) return all study equipment and supplies  within the next 4 w eeks . 
• If the subject does not return for the final evaluation, t he site will attempt to contact the family  
and reschedule the missed visit within the next 1 -4 weeks, counsel the participant on the 
importance of maintaining the assigned visit schedule , and ascertain if the family  wishes to and/or 
should continue in the study.  
• Before a participant is deemed lost to follow -up, the clinical site investigator  or designee will make 
every effort to regain contact with the participant by multiple means or by contacting designated 
  Page 26 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 alternative contacts . These contact attempts will be documented in the participant’s medical 
record or study file.  
• Should the participa nt continue to be unreachable, the participant  will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up. 
  
  Page 27 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
  
8 STUDY ASSESSMENTS AN D PROCEDURES  
 
8.1 EFFICACY ASSESSMENTS  
8.1.1  OXYGEN SATURATION  
Continuous recording of O 2 saturation using the study pulse oximeter is planned  for all infants through 
hospital discharge, and for the sub- group of i nfants recruited at hospitals participating in home oximetry 
recording ,will continue  through 43 weeks + 6 days PMA (i.e. one week following the last dose of study 
drug ).  The study oximeter will be the Masimo RAD -97, set at the minimum possible averaging time  of 2-
4 sec and a sampling rate of 1 sec (high resolution) .  The oximeter will be preset in the sleep lab mode,  
hence with no “probe off ,” “low battery,” or physiologic visual displays or alarms.   The internal data 
storage capacity of the RAD -97 oxime ter is sufficient for 28 days of continuous data collection.  
Inpatient  Phase : During the inpatient phase, the RAD -97 will be a 2nd oximeter , in addition to the one used 
for standard monitoring  in the NICU.  Continuous oximeter recordings will be obtained whenever in the 
NICU.    Data will be downloaded from the monitor, and archived by the DCC, at least every 4 weeks while 
in the NICU  and at discharge.  
Please note:  Some sites may discontinue oximeter recordings at hospital discharge.  
Outpatient  Phase :  At sites  participating in the home oximetry portion of the study, p rior to discharge, 
the family will be trained in the use of the RAD -97, and will be  asked to use the oximeter  during all sleep 
times and quiet  awake periods until 43 weeks + 6 days PMA.  A t home, therefore, we expect at least  8 – 
12 hour s of use per day, so  the memory capacity of the RAD -97 should  be sufficient to complete the  
outpatient phase .   
Following discharge , the family will be contacted within the first 2 –  3 days, and then at least weekly to 
provide support in the use of the study monitor a nd to support other aspects of the study protocol .  As 
part of their support of the use the monitor at home, study site staff will assess if the use pattern is such 
that the oximeter memory might be close to capacity, and deter mine if it is necessary to schedule  an 
additional data download.  
8.1.2  INFLAMMARORY BIOMARKERS  
An EDTA  blood sample (0.6 – 0.8 ml) to measure a panel of inflammatory biomarkers will be obtained at 
enrollment prior to randomization, and again at 38 weeks + 0 days PMA or NICU discharge, whichever 
comes first . The b lood will be  centrifuged and the resultant plasma aliquot ed into tubes and immediately 
frozen ( -80 °C). The intent is to freeze a plasma volume of at least 0.3 ml. As specified by later shipping 
instructions, the frozen samples will be batched and shipped on dry ice o vernight using shipping labels 
that will be provided.  
 
  Page 28 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Bulk analys es of inflammatory biomarker plasma concentrations  will be performed at Children’s National 
Medical Center  using a  commercially available ELISA multi- spot assay to measure inflammation -related 
proteins from different functional categories  of cytokines  and chemokines, including growth factors, and 
adhesion molecules, IFN-alpha, IL -6, Gro/CXCL1, IL -1β, IL -4-6, IL -6 rece ptor, IL -8, IL -10, IL -13, ICAM -1, 
myeloperoxidase, CRP, MCP, IGFBP -1, MIP -1a, RANTES, and TNFa.  Analytes that show strong trends or 
significance with this assay may be further analyzed with individual ELISA assays, to confirm the original 
result.  
 
8.1.3  QUANTITA TIVE MRI S TRUCTURAL, MICROSTRUCTURAL AND M ETABOLIC 
BIOMARKERS OF A CUTE BRAIN INJURY  
Our goal is to obtain baseline and follow -up b rain MRI in approximately half of the study participants ( 55 
subjects in  each study arm ).   For additional information, refer to MRI Manual.  
 At sites recruiting infants into the MRI portion of the study, i nfants will be quieted by swaddling and 
feeding before the MRI study. O
2 saturation, heart rate and temperature will be monitored and recorded 
throughout the scan. All infants will be protected from MRI scanner noise by the use of ear wax, and mini 
muffs (Natus MiniMuffs Noise Attenuators). MRI acquisition protocols will be standardized and field -
tested across all sites in Y1 Q1 -3, and MRI calibration studies will be performed t o ensure that the MRI 
scanner properties and parameter settings during the acquisition phase are correct. Conventional MRI studies will be reviewed in a standardized fashion by a pediatric neuroradiologist at each site blinded to study randomization.  
 All MRI data sets will be processed at the Advanced Pediatric Brain Imaging Research Laboratory (DBRL) 
at Children’s National Medical Center.  All quantitative MRI outcome measures are continuous and will be 
performed by a single investigator masked to randomization . Abnormalities of brain development, 
maturation, the presence of focal destructive ischemic or hemorrhagic lesions, will be documented.  
 
8.1.4  SALIVARY  CAFFEINE LEVELS  
Two salivary samples will be obtained for later analysis of caffeine concentrations, the 1st in the NICU 1 
week after starting study drug, and the 2nd, which may be either in the hospital or at home by parents , at 
about 40 weeks + 0 days PMA.  All samples will be pre-prandial. Salivary volumes of 200 -300 uL will be 
collected using commerci ally available kits (Salimetrics, State College, PA) and frozen at -20o C at home 
and then at - 20° C or colder after return to the clinical site research team for bulk analysis at the end of 
the study. Parents will return the home salivary sample at the same time as their scheduled return to the 
clinical site at study end. As specified by later shipping instructions, the frozen salivary samples will be 
batched and shipped on dry ice overnight with the pl asma samples using shipping labels that will be 
provided.  
Salivary analyses will be performed by the Biomedical Research Lab at Walter Reed National Military 
Medical Center. Sample preparation and chromatography will utilize a method validated in our 
preliminary study.89,90  Chromatography will be performed using a Waters Alliance 2695 Separations 
Module equipped with a Waters 2996 Photodiode Array detector and Waters Symmetry column.  
  Page 29 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 8.1.5  BRIEF INFANT SLEEP QUESTIONNAIRE (BISQ)  
The Brief Infant Sleep Questionnaire (BISQ) is a p arent -reported questionnaire on infant/toddler sleep 
over the prior one week .  It includes 13 items in three categories (sleep duration, night wakings, and 
method  of falling asleep).  The BISQ will be completed  by phone during th e weekly phone call that  is 
scheduled between 42 weeks 0 days and 42 weeks 6 days, or in person, at study termination if this occurs 
prior to 42 weeks + 0 days.  
 
 
8.2 SAFETY AND OTHER ASSESSMENTS  
8.2.1  TELEPHONE ASSESSMENT  OF STATUS AT HOME  
Within 1 – 3 days following hospital discharge to home, and at least weekly thereafter, study site staff will 
contact families  by phone and complete a phone contact log.  The phone contact log will document:  
• Family questions or concerns  
• Assessment of compl etion of the drug log and issues related to administration or supply of study 
drug 
• Assessment of extent of use of study oximeter  (if applicable)  and any questions, problems or 
other concerns related to study drug 
• Discussion  of upcoming study procedures  
• Assessment for occurrence of adverse events  
• Determination of use of concomitant  medications  
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERS E EVENTS (AE)  
• Adverse event means any untoward medical occurrence associated with the use of an 
intervention in humans, whether or not considered intervention -related (21 CFR 312.32 (a)).  
• Since there will be multiple participating clinical sites, centralized safety oversight will be 
coordinated by the DCC in conjunction with the ICAF principal invest igators . 
• The study does not involve an investigational new drug, but is extending the duration of caffeine treatment beyond the customary age of discontinuing caffeine treatment in the NICU. The FDA has deemed the use of caffeine in this study as consisten t with prior FDA approv al, and has 
therefor e granted an IND Exemption.   
• There is no risk in randomizing to placebo; absent enrollment in this study, infants would not be 
treated with caffeine.  
8.3.2  DEFINITION OF SERIOU S ADVERSE EVENTS (SA E)  
An adverse event ( AE) or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor,  it results in any of the following outcomes: death, a life -threatening adverse 
event, inpatient hospitalization or prolongation of existing hos pitalization, or a persistent or significant 
incapacity or substantial disruption of the ability to conduct normal life functions. Important medical 
events that may not result in death, be life -threatening, or require hospitalization may be considered 
  Page 30 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 serious when, based upon appropriate medical judgment, they may jeopardize the participant  and may 
require medical or surgical intervention to prevent one of the outcomes listed in this definition.    
Note that for the purpose of this study, delaying discharge of an infant related to achieving a specified ‘spell -free’ 
number of days  shall NOT  be considered a ‘prolongation of existing hospitalization’ for the purpose of categoriz ing 
an event as a serious adverse event.  
 
 
 
 
8.3.3  CLASSIFICATION OF AN  ADVERSE EVENT  
8.3.3.1  SEVERITY OF EVENT  
The following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.   
• Moderate – Events result in a low level of inconvenience or concern  with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  Of note, the term  “severe” does not necessarily equate to “serious” . 
8.3.3.2  RELATIONSHIP TO STUD Y INTERVENTION  
All adverse events ( AEs) will have their relationship to study intervention assessed by the clinical site 
principal investigators based on temporal relationship and clinical judgment. The degree of certainty 
about causality will be graded using the categories below :  
• Definitely Related –  There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event occurs in a plausible time relationship to 
study intervention administration and cannot be explained by concurrent disease or other drugs 
or chemicals.  
• Probably Related –  There is evidence to suggest a causal relatio nship, and the influence of other 
factors is unlikely. The clinical event occurs within a reasonable time after administration of the study intervention , is unlikely to be attributed to concurrent disease or other drugs or chemicals.  
• Potentially Related –  There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medication). However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other 
concomitant events). An AE ma y rate as “possibly related” soon after discovery, but it can be 
flagged as requiring more information and later be upgraded to “probably related” or “definitely related”, as appropriate.  
• Unlikely to be related –  A clinic al event whose temporal relationship to study intervention 
administration makes a causal relationship improbable  and other drugs or underlying disease 
provides plausible explanations (e.g., the participant’s clinical condition, other concomitant treatments ). 
• Not Related –  The AE is completely independent of study  intervention administration, and/or 
evidence exists that the event is definitely related to another etiology. The  alternative, definitive 
etiology must be documented by the clinic al care team . 
8.3.3.3  EXPE CTEDNESS  
  Page 31 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 • The clinical site principal investigators  will be responsible for determining whether an adverse 
event ( AE) is expected or unexpected.  An AE will be considered unexpected if the nature, severity, 
or frequency of the event is not consistent with the well -established risk information previously 
described for caffeine.  
 
 
• Expected AE for caffeine treatment can include tachycardia, feeding intolerance, jitteriness. 
However, no significant AE are expected since all enrollees will have previously tolerated routine 
caffeine treatment at systemic concentrations similar to those achieved in this study.    
  
8.3.4  TIME PERIOD AN D FREQUENCY FOR EVEN T ASSESSMENT AND FOL LOW- UP 
• The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the attention 
of clinical care personnel as part of routine NICU care, or by research staff or parents . 
• All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on 
the appropriate  case report form  (CRF). Information to be collected includes event description, 
time of onset, clinician’s assessment of severity, relationship to study prod uct (assessed only by 
those with the training and authority to make a diagnosis), and time of resolution/stabilization of 
the event.  
• All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
• Any medical condition that is present at the time that the participant is enroll ed will be considered 
as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it wi ll be recorded as an AE.  
• Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of ea ch episode.   
• Designated study site research staff will record all reportable events occurring in the NICU  
starting  from when informed consent is obtained until the last day of study participation  (for non -        
serious AEs) or 30 days (for SAEs) after the last day of study participation.   NOTE: Last day of study 
participation may be any of the following:  
o end-of-study visit  
o follow -up MRI visit  
o Lost-to-follow -up determination date  
• After discharge home, research staff will query parents at least weekly abo ut the occurrence of 
AE/SAEs since the last contact .  Events will be followed for outcome information unt il resolution 
or stabilization.  
 
  
8.3.5  ADVERSE EVENT REPORT ING  
AEs and SAEs  will be documented in the source records and recorded on the eCRFs using accepted medical terms 
and/or the diagnoses that accurately characterize the event. When a diagnosis is known, the AE term recorded on 
the eCRF will be the diagnosis rather than a constellation of symptoms. The clinical site principal investigator s or 
  Page 32 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 their des ignee will assess all AEs for seriousness, relationship to investigational product, severity, expectedness, and 
other possible etiologies. When an event has not resolved by study closure, it will be documented on the AE eCRF 
as “ongoing”.  
The timeframe for the collection of AEs and SAEs is noted above in section 8.3.4.  
 
 
 
 
  
8.3.6  SERIOUS ADVERSE EVEN T REPORTING  
All SAEs must be reported promptly (within 24  hours) to the study DCC , whether or not the event is 
considered related to study product. Further, the clinical site principal investigators should comply with 
relevant clinical study site  IRB requirements  on reporting SAEs.  
Clinical site principal investigators must submit additional information as soon as it is available on the SAE 
report form. The study DCC  will report unexpected SAEs associated with the use of the drug as required .  
Clinical site principal investigators must follow all relevant regulatory requ irements as well as specific 
policy regarding the timely reporting of SAEs to the study DCC and the clinical study site  IRB.  
Reporting to the study DCC  does not fulfill the clinical site principal investigator’s duty to report all 
unanticipated problems involving risk to human subjects or others to the IRB. The clinical site principal 
investigators  will notify the clinical study site  IRB and ICAF principal investigators .  
• Any AE considered serious by the clinical site principal investigator or an ICAF principal 
investigator,  or which meets the definition of an SAE included in Sect ion 8. 3.2, Definition of 
Serious Adverse Event s must be submitted on an SAE form to the Data Coordinating Center ( DCC).   
• The DSMB  will receive  expedited  notification of all SA Es, even if not thought to be related to study 
intervention .   
• All serious adverse events ( SAEs ) will be followed until satisfactory resolution or until the clinical 
site principal investigator deems the event to be chronic or the participant is stable. Other 
supporting documentation of the event may be requested by the Data Coordinating Center ( DCC) 
and should be provided as soon as possible.  
 
8.3.7  REPORTING EVENT S TO PARTICIPANTS  
Not Applicable  
 
 
8.3.8  EVENTS OF SPECIAL IN TEREST  
• Although rare, infants bo rn at ≤30  weeks gestation and discharged home are at risk for an 
apparent life -threatening event (ALTE, or brief resolved unexpected event,  BRUE) or for sudden 
unexpected infant death (S UID) 
  Page 33 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 • Infants enrolled in this study are at no greater risk, and perhaps at even less risk, for such events 
than infants not enrolled   
 
8.3.9  REPORTING OF PREGNAN CY  
Not applicable  
 
8.4 UNANTICIPATED PROBLE MS 
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP) 
Federal regulations  (45 CFR Part 46/32 CFR 219)  require that unanticipated problems involving risks to subjects or 
others be promptly reported to the IRB. These events encompass a broader category of events than SAEs and may 
include issues such as problems with lo ss of control of subject data or the investigational product; adverse 
psychological reactions; or breach of confidentiality. Risks to others ( e.g., program personnel) must also be reported.    
 
The Office for Human Research Protections ( OHRP ) considers unan ticipated problems involving risks to 
participants or others to include, in general, any incident, experience, or outcome that meets all  of the 
following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures tha t are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the 
participant population being studied;  
• Related or possibly related t o participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
• Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 
 
8.4.2   UNANTICIPATED PROBLE M REPORTING  
The clinical site principal investigator s will report unanticipated problems ( UPs) occurring from the time 
the informed consent form is obtained  through 30 days after the last day of study participation to the 
clinical study site  Institutional Review Board ( IRB) and t o the Data Coordinating C enter ( DCC)/ICAF  
principal investigators  The UP report will include the following information:  
• Protocol identifying information: protocol title and number, Clinical site principal investigator’s  
name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP ;  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP . 
 
To satisfy the requirement for prompt reporting, UP s will be reported using the following timeline:   
 
• UPs will be reported to the clinical study site IRB and to the DCC  and PI/Co -PI within  1 business 
day  of the investigator becoming aware of the event.  
  Page 34 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
  
All UPs should be reported to appropriate institutional officials (as required by an institution’s written 
reporting procedures), the supporting agency head (or designee), and the Office for Human Research 
Protections ( OHRP ) promptly after the clinical s tudy site IRB’s receipt of the report of th e problem from 
the clinical site principal investigator s. 
 
 
 
 
9 STATISTICAL CONSIDER ATIONS   
 
9.1 STATISTICAL HYPOTHES ES 
Primary Objective  1: Compare the extent of IH exposure , from randomization through  42 weeks + 6 
days PMA (within each gestational week and overall), in infants randomized to extended caffeine 
treatment to infants assigned to receive placebo. We hypothesize that caffeine will reduce the  extent of 
IH compared to placebo, and that this caffeine effect will  persist through 42 w eeks PMA.    
 
Primary Objective  2: Compare changes in a panel of inflammation -related  cytokines and chemokines, 
from enrollment to the target age of 38 w eeks + 0 days PMA, in infants randomized to extended  caffeine  
treatment to infants assigned to receive placebo . We hypothesize that continuing caffeine treatment will 
be associated with less inflammation compared to placebo.  
 
Primary Objective  3: Compare changes in quantitative MRI structural, microstructural and me tabolic 
biomarkers of acute injury, from enrollment to 43 -46 weeks PMA,  in infants randomized to extended  
caffeine  treatment to infants assigned to receive placebo . We hypothesize that continued caffeine 
treatment compared to placebo will be associated wit h 1) greater white matter microstructural 
organization, 2) improved neuronal metabolism, and 3) greater regional brain volume.  
Secondary Objective 1: Examine the association between salivary caffeine concentrations and IH  
outcomes at the one week post rand omization and  40 weeks + 0 days PMA assessments.  We 
hypothesize that those with higher salivary caffeine concentrations will have less severe IH outcomes . 
Secondary Objective 2: Determine whether caffeine effects on changes in inflammatory or MRI 
biomarkers from baseline to follow -up are mediated by caffeine -related reduced IH .  We hypothesize that 
caffeine effects on changes in inflammatory or MRI biomarkers will be at least partially mediated by 
reduced IH.  
9.2 SAMPLE SIZE  DETERMINATION  
  Page 35 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Sample Size:  We will randomize 220 infants, 110 in each treatment group, with  ≥100 infants/group 
available for final analyses. Sample size considerations focus on PMA week -specific differences between 
the extended caffeine vs. placebo infants for our primary outcome o f #sec/day < 90% saturation from 36 
to 42 weeks PMA. Preliminary data showed effect sizes at 37 and 38 weeks PMA of 0.87 and 0.73.   With 
the decline in IH  with increasing age, we expect that 1) the caffeine effect may decline and 2) moderate 
effects will be needed to achieve a meaningful reduction in  IH to 42 w eeks PMA.   Therefore, we consider 
an effect size of 0.50 to represent a meaningful detectable difference between groups.   Final samples of 
n=100 per group gives 82% power to detect this effect, testing at the overall 2 -tailed .05 level with a 
familywise Type I error correction adjusting for multiple testing across weeks. Secondary outcomes of # IH 
event s and #sec < 80% saturation/day showed effect sizes at 38 weeks PMA of 0.73 and 0.46 in our pilot 
data.  
 
 
9.3 POPULATIONS FOR A NALYSES  
The intention -to-treat  (ITT) population will consist of all randomized subjects.   
 The mod ified intention -to-treat (mITT) p opulation will include all subjects who took at least one dose of 
study drug and who have data available for efficacy outcomes.   
 The safety population will consist of all randomized subjects who receive a dose of study drug.  
 
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
Statistical significance will be declared at the two-sided p <0.05  level ; when appropriate , correction for 
multiple comparisons will be employed.  For analyses  of primary and secondary objectives,  we will adjust 
for demographic and clinical differences.   When employed, tests for interaction will at the 0.1 alpha level.  
Results  will be presented through measures of effect and 95%  confidence intervals . If lost to follow -up 
exceeds the 10% anticipate d under sample size considerations, multiple imputation on the intent -to-treat 
population will be used for sensitivity analyses that account for missing data.  All computations will be 
performed using the latest available version of SAS® . 
 
Demographic variables and subject characteristics will be summarized descriptively by treatment assignment and overall. Continuous parameters will be summarized using descriptive statistics (N, mean,  
median, standard deviation, minimum and maximum value). Categorical demog raphic  parameters, such 
as gender, will be summarized as a percentage  of the  population.
 
9.4.2  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN TS  
Primary Objective 1:  Compare the extent of IH exposure , from randomization through  42 w eeks + 6 
days  PMA (within each gestational week and overall), in infants randomized to extended caffeine 
treatment to infants assigned to receive placebo.  
Analyses  for this objective  will be performed on the mITT  population  and compare those randomized to 
extended caffeine vs. placebo.  To be included in  IH analyses , a subject must have had at least 10 hours of 
acceptable quality oximetry data recorded within at least one PMA week. A single overall baseline SaO 2 
  Page 36 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 will be determined for each infant, confirmed in our pilot stud y to be ≥95% for the PMA  weeks bein g  
studied. An  IH event is defined as SaO 2 decrease ≥10% (event threshold) and lasting ≥5 sec; the event ends 
when SaO 2 increases above the event threshold. For sec of SaO 2 below threshold, all sec below the 
threshold are included. We will compare extended caffeine vs. placebo infants on measures of IH, with # 
of sec <90% saturation/day our primary outcome. Our pilot data showed that # of sec <90% optimally 
discriminates between infants on vs. not on extended caffeine, with  high correlation between #sec < 90% 
saturation/day and multiple other measures to quantify IH  which will be secondary outcomes, including 
#IH events/day, # sec < 80% saturation/day, nadir saturation during events, duration of events 
(Spearman’s correlatio ns r >0.90, and AOC during events below 90% and 80% threshold saturation 
(r=0.83).90 Preliminary data showed that these outcomes follow a log -normal distribution, and data will 
be log- transformed for analysis; non -parametric procedures will be considered as an alternative analytic 
approach if warranted by the distribution of the IH  outcome s. Exploratory analyses will also compare 
caffeine vs. placebo on heart rate data.  As a check on randomization, preliminary analyses will compare 
the two study groups on key characteristics including gestational age, birth weight,  infant sex, morbidity 
(e.g., necrotizing enterocolitis, mild BPD), and severity of illness measures; variables found to differ 
meaningfully between groups will be controlled for in primary analyses through multiple linear regression models. Primary analyses will determine how lon g extended caffeine provides an advantage over placebo 
by testing PMA week -specific differences between study groups through multiple regression models 
controlling for key covariates using Holm’s family -wise error adjustment to account for multiple testing  
across PMA weeks.   
Primary Objective 2:  Compare changes in a panel of inflammation -related  cytokines and chemokines , 
from enrollment to the target age of 38 w eeks + 0 days PMA, in infants randomized to extended caffeine 
treatment to infants assigned to r eceive placebo .  
Analyses for this objective will be performed on the mITT population and compare those randomized to 
extended caffeine vs. placebo.  To be included in the analyses a subject must have had a baseline/follow -
up pair of blood samples for whic h at least one biomarker was measured on both samples.  Analysis will 
focus on change in inflammatory biomarker levels over the study period.  Preliminary analyses will 
examine the distribution of biomarkers, and data will be transformed (e.g., logged) as appropriate for 
analysis. Two approaches will be taken for the primary analyses, comparing changes in biomarkers over 
the study period in extended caffeine vs. placebo infants.  First, we will conduct separate analyses of each 
inflammatory biomarker using linear regression models to compare study groups at study completion, 
controlling for baseline levels as well as key covariates including morbidities that might be associated with 
inflammation, using the Benjamini and Hochberg method to account for multipl e testing by controlling 
the false discovery rate.  Second, we will examine the structure of the biomarker data using data reduction 
procedures of factor analyses (identifying latent variables reflected by the set of biomarkers) and latent 
profile analysis  (identifying subgroups of infants with similar patterns of biomarker profiles). Extended 
caffeine vs. placebo infants would then be compared on the summary measures of inflammation 
biomarkers resulting from these analyses.  
  Page 37 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Primary Objective 3 : Compare changes in quantitative MRI structural, microstructural and metabolic 
biomarkers of acute injury , from enrollment to 43 -46 weeks PMA, in infants randomized to extended 
caffeine treatment to infants assigned to receive placebo .  
Analyses for this objective will be performed on the mITT population and compare those randomized to 
extended caffeine vs. placebo.  To be included in the analyses a subject must have had a baseline/follow -
up pair of MRI studies completed from which  at lea st one MRI endpoint could be measured on bot h 
assessments.  
Primary neuroimaging outcome measures will include microstructural measures derived from our DTI 
analyses (FA/MD) and proton MRS.  Secondary outcomes will include regional tissue volumes. Individual 
end-of-study MRI parameters will be compared through analysis of covariance multiple linear regression 
models controlling for the MRI parameter at baseline along with key covariates including indicators of 
comorbidities potentially associated with brain development , using the Benjamini and Hochberg method 
to account for multiple testing by controlling the false discovery rate.  .  
Secondary Objective 1: Examine the association between salivary caffeine concentrations and IH 
outcomes at the one week post randomization and  40 weeks + 0 days PMA assessments.  
Analyses will examine the association between salivary caffeine levels and IH outcomes, both at the end 
of the inpatient stay and at study completion. Caffeine levels at home will also be used to verify protocol 
adherence. Secondary analyses will also include relationship between individual neonatal morbidities and 
extent of IH in caffeine and placebo groups. Exploratory analyses will model the trends in IH  parameters 
over time in the extended caffeine an d placebo groups using mixed -effects linear regression models for 
longitudinal data.  Should missing data become a problem, multiple imputation methods will be used to 
account for potential bias in the complete case analysis.  
Secondary Objective 2:  Determine whether changes, from baseline to  follow -up, in inflammatory or 
MRI biomarkers are mediated by caffeine -related reduced  IH. 
 
We will also examine  IH levels during the study period as a mediator of the extended caffeine effect.  Initial 
analyses will examine associations between IH parameters and inflammatory biomarkers, to determine 
which IH measures are most strongly correlated with inflammation at s tudy completion. Linear structural 
equation mediational models will be used to determine whether any associations between extended caffeine treatment and changes in inflammatory biomarkers can be explained by IH  parameters during 
the study period. The rela tionship between neonatal morbidities, Inflammation, and response to caffeine 
will also be assessed.  
Similarly we will also examine associations between changes in MRI parameters and levels of  IH during 
the study period through correlation and linear regre ssion models with the goal of determining IH  
parameters most strongly associated with brain injury. Structural equation mediational models will 
determine whether any associations between extended caffeine and MRI changes can be explained by 
the level of IH  activity during the study.  
 
  Page 38 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 9.4.3  SAFETY ANALYSES  
Analyses of safety outcomes will be performed on the safety population consisting of all randomized 
subjects who receive a dose of study drug.  Descriptive data on safety outcomes will be provided by 
treatment g roup . 
 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS 
 
10.1 REGULATORY, ETHICAL , AND S TUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1 INFORMED CONSENT PROCESS  
• In collaboration with the clinical care team, research staff will screen all NICU patients born at ≤30 
weeks gestation and receiving routine caffeine treatment for study eligibility  
• Clinical care staff will inform parents of this ongoing research study and inform research staff of 
families desiring additional study information  
• Parents will not be approached for f ormal consent  before the infant is 32 weeks + 0 days PMA.  
  
 
10.1.1.1  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS PROVIDED TO  
PARTICIPANTS 
• All informational documents and consent material to be provided to parents of potential study 
subjects will be submitted to study site IRB’s and utilized in accordance with procedures approved 
by the IRB.  
  
 
10.1.1.2  CONSENT PROCEDURES A ND DOCUMENTATION  
Informed consent is a process that is initiated prior to parental agree ment  to participate in the 
study and continues throughout the duration of the study. The Consent Form will be Institutional 
Review Board ( IRB)-approved and the parent(s)  will be asked to read and review the document. 
The investigator , or their designee, will e xplain the research study to the parent  and answer any 
questions that may arise. A verbal explanation will be provided in terms suited to the parent ’s 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as resear ch participants.  Parent s will have the opportunity to carefully review the consent form 
and ask questions prior to signing, and will have the opportunity to discuss the study with family 
or surrogates or to think about it prior to agreeing to participate. A parent  will sign the informed 
consent document prior to any procedures being done specifically for the study. Par ents will be 
informed that participation is voluntary and that they may withdraw from the st udy at any time, 
without prejudice.  A copy of the informed consent document will be given to the par ents for their 
records. The informed consent process will be conducted and documented in the source document (including the date), and the form signed, befo re the subjec t undergoes any study -
specific procedures. The rights and welfare of the subject s will be protected by emphasizing to 
  Page 39 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 parents  that the quality of medical care will not be adversely affected if they declin e to participate 
in this study.  
• As may be deemed necessary by the clinical site, t he Consent Form will be available in Spanish as 
well as in English, and a Spanish translator will be available whenever needed.  
10.1.2 STUDY DISCONTINUATIO N AND CLOSURE  
This study may be temporarily suspended or p rematurely terminated if there is sufficient reasonable 
cause.  If the study is prematurely terminated or suspended, the  clinical site principal investigators  will 
promptly inform study participants, the clinical study site In stituti onal Review Board ( IRB), and will provide 
the reason(s) for the termination or suspension.   
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration o f efficacy that would warrant stopping    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 
  
10.1.3 CONFIDENTIALITY AND P RIVAC Y  
Information about study subjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a 
signed subject authorization informing the subject  of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their au thorization for use of their PHI.  
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, 
retains the ability to use all information collected prior to the revocation of subject authorization.  For 
subject s that have revoked authorization to collect or use PHI, attempts should be made to obtain 
permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study 
period.  
Participant confidentiality and privacy is s trictly held in trust by the participating investigators, their staff, 
and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of biological 
samples and genetic tests in addition to the clinical information relating to  participants.  Therefore, the 
study protocol, documentation, data, and all other information generated will be held in strict confidence. 
  Page 40 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 No information concerning the study or the data will be released to any unauthorized third party without 
prior written  approval of the sponsor.  
 
All research activities will be conducted in as private a setting as possible.  
 
Representatives of the clinical site Institutional Review Board ( IRB) or DSMB  may inspect all documents 
and records required to be maintained by the clinical site principal investigator s, including but not limited 
to, medical records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 The study participant’s contact information will be securely stored at each clinical study site for internal 
use during the study. At the end of the study, all records will continue to be kept in a secure lo cation for 
as long a period as dictated by the clinical site  IRB, Institutional policies, or sponsor requirements.  
 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored a t the Data Coordinating Center. This will not include the participant’s 
contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study m anagement systems used by 
clinical study sites and by Data Coordinating Center research staff will be secured and password protected. 
At the end of the study, all study databases will be de- identified and archived at the Data Coordinating 
Center . 
 
 
10.1.4 FUTURE USE OF STORED SPECIM ENS AND DATA  
See Section 10.1. 3, Confidentiality  and Privacy and Section 10.1.9, Data Handling and Record Keeping , 
for further information on future use of study records.  
 Data collected for this study wi ll be analyzed and stored at Bo ston University Medical Center ( Data 
Coordinating Center (DCC)). After the study is completed, the de- identified, archived data will be 
transmitted to and stored at the Slone Epidemiology Center at Boston University , for use by other 
researchers including those outside of the study. Permission to transmit data to the Slone Epidemiology 
Center at Boston University  will be included in the informed consent.  
 
During the conduct of the study, an individual participant ca n choose to withdraw consent to have 
biological specimens stored for future research. However, withdrawal of consent with regard to biosample storage may not be possible after the study is completed.  
 
When the study is completed, access to study data and/or samples will be provided through  the DCC . 
 
 
10.1.5 KEY ROLES  AND STUDY GOVERNANCE  
Principal Investigator  
Carl E. Hunt, MD  
Professor of Pediatrics  
  Page 41 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Children’s National Medical Center/Children’s 
Research Institute   
111 Michigan Avenue, NW  Washington, DC 20010  
301-767-5514  
carl.hunt@usuhs.edu  
chunt@childrensnational.org  
 
Co-Principal Investigator  
Eric Eichenwald, MD   
Chief, Division of Pediatrics  
Perelman School of Medicine  
University of Pennsylvania                                                              
Children’s Hospital of Philadelphia                                                                      
3401 Civic Center Blvd., Philadelphia PA  19104  
215-452-6951  
617-966-7024 (cell)  
Eichenwald@email.chop.edu  
Study Leadership  
• This is a Multiple PI  grant application, with Drs. Hunt and Eichenwald as Co -PIs.  
• There will be a Steering Committee , chaired in rotating years by Drs. Hunt and Eichenwald. Other 
members will be Drs. McEntire (Project Director), Corwin (DCC), Heeren, Limperopoulos, Poets, 
Darnall and Revenis and a representative from each clinical site.  This group will be responsible for 
coordinating and managing all phases of this study.  
• Executive Committee (EC): Drs. Hunt and Eichenwald (Co -PI), Dr. McEntire (Project Director), and 
Dr. Corwin (DCC) will provide overall study oversight and coordination, and resolution of any site -
specific issues.  
10.1.6 SAFETY OVERSIGHT  
Safety oversight will be under the direction  of a Data and Safety Monitoring Board ( DSMB ) composed of 
individuals with the appropriate expertise, including content and statistical expertise. Members of the 
DSMB should be independent from the study conduct and free of conflict of interest, or measure s should 
be in place to minimize perceived conflict of interest.  The DSMB will meet at least semiannually to assess 
safety and efficacy data on each arm of the study. The DMSB will operate under the rules of an approved 
charter that will be written and re viewed at the organizational meeting of the DSMB. At this time, each 
data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to the executive committee and to NICHD  staff.
 
10.1.7 CLINICAL MONITORING  
There will be no for mal on site clinical monitoring of data. All study data will be managed at the data 
coordinating center (DCC). Each subject will be assigned a unique study identifier code. Data entered by sites will be via a web -based portal and will flow directly into the main study Microsoft Access database. 
Standard quality control and cleaning procedures will be applied to ensure that accurate data entry has 
occurred. All study data will be stored on secure password -protected computer servers that are backed 
up automatically daily, and maintained by the Information Systems staff. The database will be 
programmed to produce weekly reports tracking enrollment and follow -up completion and other periodic 
  Page 42 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 reports as required.  Virtual meetings between DCC and site investigators will be held frequently to 
monitor enr ollment and track overall study conduct and any difficulties encountered.  
10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL  
See Section 10.1. 7, Clinical Monitoring . 
 
10.1.9 DATA  HANDLING  AND RECORD  KEEPING   
See Section 10.1.7, Clinical Monitoring  
10.1.9.1  STUDY RECORDS RETENT ION  
Study documents will be retained for a minimum of 2 years since the formal discontinuation of clinical 
development of the study intervention . These documents may  be retained for a longer period, however, 
if required by local regulations.  
10.1.10  PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonization  Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP ) requirements. The 
noncompliance may be either on the part of the parti cipant, the clinical site principal investigators, or the 
study site staff. As a result of deviations, corrective actions are to be developed by the site and 
implemented promptly.  
 These practices are consistent with ICH GCP :  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 No protocol deviations will be approved. However, it will be the responsibility of the clinical site principal  
investigators  to use continuous vigilance in order t o identify and report deviations within 5-10 working 
days of identification of the protocol deviation, or within 5-10 working days of the scheduled protocol -
required activity.  All deviations must be addressed in study source documents, reported to the clinical 
site PI, DCC, and NICHD  Program Official.  Protocol deviations must be sent to the reviewing Institutional 
Review Board (IRB)  per their policies . The site investigator  is responsible for knowing and adhering to the  
reviewing IRB requirements. Further details about the handling of protocol deviation s will be included in 
the MOP.  
 
 
 
10.1.11  PUBLICATION AND DATA  SHARING POLICY  
 
• The Executive Committee will be responsible for developing publication procedures and resolving 
authorship issues.  
• This study will  be conducted in accordance with the National Institutes of Health ( NIH) Public 
Access Policy, which ensures that the public has access to the published results of NIH funded 
research. It requires scientists to submit final peer- reviewed journal manuscripts that arise from 
NIH funds to the digital archive PubMed Central  upon acceptance for publication.  
• This study will comply wit h the NIH Data Sharing Policy and Policy on the Dissemination of NIH -
Funded Clinical Trial Information and the Clinical Trials Registration and Results Information 
  Page 43 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Submission r ule. As such,  this trial has been  registered at ClinicalTrials.gov  ([STUDY_ID_REMOVED]) , and 
results from this  trial will be submitted to ClinicalTrials.gov.  In addition, every attempt will be 
made to publish results in peer -reviewed journals.   
• Data from this study may be request ed from other researchers after the completion of the 
primary endpoint by contacting the DCC .  
10.1.12  CONFLICT OF  INTEREST  POLICY  
The independence of this study from any actual or perceived influence is critical.  Therefore , any actual 
conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect 
of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest 
will be required to have su ch conflicts managed in a way that is appropriate to their participation in the 
design and conduct of this t rial.  The study leadership in conjunction with NICHD has established policies 
and procedures for all study group members to disclose all conflicts of interest and will establish a 
mechanism for the management of all reported dualities of interest.  
10.2 ADDITIONAL CONSIDERA TIONS  
None  
  
  Page 44 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 10.3 ABBREVIATIONS  
 
AE Adverse Event  
ANCOVA  Analysis of Covariance  
CFR Code of Federal Regulations  
CMP  Clinical Monitoring Plan  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CRF Case Report Form  
DCC Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data Safety Monitoring Board  
EC Ethics Committee  
eCRF Electronic Case Report Forms  
FA Fractional Anisotropy  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICH International Conference on Harmonization   
ICMJE  International Committee of Medical Journal Editors  
IH Intermittent Hypoxia  
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ISM Independent Safety Monitor  
ITT Intention -To-Treat  
LSMEANS  Least -squares Means  
MD Mean Diffusivity  
MOP  Manual of Procedures  
MRI/MRS  Magnetic Resonance Imaging / Magnetic Resonance S pectroscopy  
MSDS  Material Safety Data Sheet  
NCT National Clinical Trial  
ICU Neonatal Intensive Care Unit  
NIH  National Institutes of Health  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
PMA  Postmenstrual age  
QA Quality Assurance  
QC Quality Control  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SOA  Schedule of Activities  
SOP Standard Operating Procedure  
TDD  Total D aily Dose  
UP Unanticipated Problem  
US United States  
  
  Page 45 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 10.4 PROTOCOL  AMENDMENT  HISTORY  
 
Changes in Protocol version 2.0, dated 24 NOV 2018 compared to the preliminary 
protocol version 1.1, dated 12 JUN 2018  
Location of Change  Description of Change  Brief Rationale  
Section 1.1  Enrollment start date 
changed to December, 
2018  Estimated approval date for Version 2.0  
Section 1.2 Study  Changed randomization 
from 32+1 to 32+0  It is possible to do randomization on same  day as enrollment  
Section 5.2  Changed wording on 
exclusion #2 and #3 from 
“history of or current 
treatment for…” to 
“current or prior treatment 
for…”  Clarify wording to show the exclusions are if the infant was 
treated for the conditions, not just diagnosed with the conditions.  
Section 6.1.2  Deleted “simple syrup” in 
multiple sentences. Same deletion  in other sections 
as needed.  Simple syrup not necessary component of study drug; cherry 
syrup sufficient.  
Section 6.2.1  For specific components 
of compounded study drug, refer to Pharmacy 
Manual  Pharmacy Manual the appropriate location for this detailed 
information  
Section 6.2.2  Stock study drug bottles 
can be stored, refrigerated, for up to 30 
days instead of 90 days  As recommended by Investigational Drug Service, according 
to USP guidelines  
Sections  6.5.1, 7.1,  
8.3.3.2, 8.3.3.3 , 8.3.6, 8.4.2, 10.1. 2, 10.1.3, 
10.1.10    Changed “study PI, 
clinical site PI, primary care provider ” to 
“clinical site principal 
investigators”  throughout 
document, and “PI” to 
“ICAF PI”  Make wording consistent for “clinical site PI” and “ICAF PI “ 
throughout document  
Section 8.1.4  Salivary Caffeine Levels, 
changed to “20 degrees or 
colder, -80 C is okay, if 
more convenient to store 
in same freezer as blood 
samples”  Saliva samples must be frozen at 20 degrees or colder to 
prevent evaporation.  
Section 8.3.4  Last day of study 
participation may be defined as “end of study 
visit, follow up MRI, or lost-to-follow -up 
determination date”  Clarify definition of last day of study participation  
Section 8.3.5  Adverse Event Reporting 
for AEs and SAES from 
time informed consent is 
signed through 30 days Clarify timeframe for collection of AEs and SAEs  
  Page 46 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 after the last day of study 
participation  
Section 8.4.2    Unanticipated problems 
need to be reported from 
when informed consent is 
signed through 30 days 
after the last day of study 
participation  Clarify timeframe for reporting unanticipated problems  
Changes in Protocol version 3.0, dated 08 AUG 2019 compared to version 2.0, dated 24 NOV 2018  
Location of Change  Description of Change  Brief Rationale  
Section 1.1  Two caffeine levels will 
be obtained, the 1st at one 
week after beginning 
study drug, ADDED: but 
no later than 14 days post -
first-dose  Added window of 14 days post -first-dose to assist with 
protocol compli ance  
Section 1.1  Inflammatory biomarkers 
will be measured at study 
enrollment and again at 
38+0 ADDED: plus or 
minus 3 days  Added window of + or – 3 days to assist with protocol 
compliance  
Section 1.3  Under heading “1 week 
on study drug” ADDED: “up to 14 days post 1
st 
dose”  Added window of 14 days post -first-dose to assist with study 
compliance  
Section 1.3  Under footnote 3, 
ADDED: “+ or –  3 days” 
window to 2nd sample 
collection time  Added window of + or – 3 days to assist with protocol 
compliance  
  
  Page 47 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Section 5.1  Inclusion Criteria #5 
changed from “ Breathing 
room air with no 
ventilatory support” to 
“Breathing room air with no ventilatory support for 
≥ 12 hours and not 
expected to relapse (Note 
that infants on room air 
with ≤ 2.0 L/min nasal air 
flow the rapy will NOT  be 
considered to be on 
ventilatory support). ” 
 To specify the duration of time needed of ventilatory support 
to satisfy this criterion, and to define what should be 
considered ventilatory support in a manner that is consistent 
with typical clinical management.  
Section 6.2.2  Removed “containing 
dilute oral cherry 
solution”  This detail is no longer correct and was meant to be removed 
from the protocol with the updated information now included 
in detail in the Pharmacy Manual.   
Section 6.2.2  Examples changed “20 
mg/1mL” to 10 mg/1 mL  Current caffeine formulation, which has been updated in the 
Pharmacy Manual, is 10 mg/mL.  
Section 6.2.2  Deleted “refrigerated”, 
and replaced with “at 
room temperature”  This detail is no longer correct and was co rrected to reflect the 
instruction to store the current formulation at room 
temperature.   
Section 6.2.2  Deleted “provided a 2nd 
bottle…” and replaced 
with “a sufficient quantity 
of either the active drug 
(caffeine base) or placebo 
to last until 42 weeks + 6 
days (BUD 90 days).”  This detail is no longer correct and was corrected to reflect the 
90 day BUD for the current formulation .   
  
  Page 48 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Section 8.1.4  Replaced Prior Text : 
“Two salivary samples 
will be obtained for later 
analysis of caffeine 
concentrations, the 1st in 
the NICU 1 week after 
starting study drug, and 
the 2nd at home by 
parents at about 40 
weeks + 0 days PMA.  
All sample s will pre -
prandial. Salivary 
volumes of 200- 300 uL 
will be collected using 
commercially available 
kits (Salimetrics, State 
College, PA) and frozen at -20
o C at home and 
then at  -80° C after 
return to the clinical site research team  in the 
same freezer as the 
plasma samples) for bulk 
analysis at the end of the 
study.  
Revised Text:    “Two 
salivary samples will be obtained for later 
analysis of caffeine 
concentrations, the 1
st in 
the NICU 1 week after 
starting study drug, and 
the 2nd, which may be 
either in  the hospital or at 
home by parents, at 
about 40 weeks + 0 days 
PMA.  All samples will 
be pre -prandial. Salivary 
volumes of 200- 300 uL 
will be collected using 
commercially available 
kits (Salimetrics, State 
College, PA) and frozen 
at -20o C at home and 
then at -20° C or colder 
after return to the clinical site research team for bulk analysis at the end 
of the study.”  
 Text revised to clari fy that 2nd salivary sample may be 
either in the hospital or at home and the freezer 
temperature is permitted to be - 20 degrees or colder 
hospital freezer.  
Sections 8.3.2 and 8.3.3  Removed first sentence 
in section 8.3.3 and 
added it as the last 
sentence in 8.2.2 to fix Correction of typographical error.  
  Page 49 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 formatting pagination 
error.  
Section 8.3.5  Timeframe for the 
collection of AEs and 
SAEs…” has been 
changed to reference the timeframe which was 
previously provided in 
Section 8.3.4., which 
states, “…AEs through 
the last day of study 
participation, and SAEs until 30 days after the 
last day of study 
participation.”  Section 8.3.4 correctly stated the policy, and there was no 
need to repeat it in section 8.3.5, which was also not worded consistently.  
   
Section 8.3.8  Changed from “(ALTE, 
or brief resolved 
unexpected event, 
BRUE) or for sudden 
unexpected infant death 
(SIDS)” to “(ALTE, or 
brief resolved 
unexpected event, BRUE) or for sudden 
unexpected infant death 
(SUID)”      
 Correction of acronym for Sudden Unexpected Infant 
Death  
CHANGES FROM 3.0 to 4.0  
Location of Change  Description of Change  Brief Rationale  
1.1 Study Description:  5th sentence:  
CHANGED FROM:  
If, based on standard 
clinical criteria, the last 
dose of routine caffeine 
is given on or before the 
day the infant is 36 
weeks + 5 days PMA, 
then on the day 
following their last dose 
of routine caffeine treat ment, infants will 
be randomized 
(110/group) to extended 
caffeine treatment or 
placebo.  
  
CHANGED TO : 
If, based on standard 
clinical criteria, the last 
dose of routine caffeine 
is given on or before the 
day the infant is 36 To allow a 3 -day window from last day of clinical 
caffeine to randomization and dosing.  
  Page 50 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 weeks + 5 days PMA,   
then, ide ally,  on the day 
following, but no later 
than the third calendar 
day following, their last dose of routine caffeine 
treatment, infants will be 
randomized (110/group) 
to extended caffeine 
treatment or placebo.  
 
 
1.1 S YNOPSIS  Study 
Population  Remove “one of 8” 
participating hospitals  We continue to increase the number of participating 
hospitals to help increase enrollment.  
1.1 SYNOPSIS Description 
of Sites/Facilities  Remove “8” (hospitals) 
and “six” (metropolitan 
areas)  We continue to increase the number of participating 
hospitals to help increase enrollment.  
1.1 SYNOPSIS Study 
Duration  Change sentence from 
“Enrollment is scheduled 
to start in December, 
2018 and wil l continue 
through the end of 2021, 
with completion of 
follow -up and data 
analyses extending 
through May of 2022” 
TO:.”Enrollment is 
scheduled to start in 
December, 2018 and will 
continue at least through 
May, 2022, with completion of follow -up 
and data an alyses 
thereafter.”  To allow time for adequate enrollment which has 
been delayed partially due to COVID  impacts.  
1.2 Study Schema  2nd-to-last sentence 
CHANGED FROM:  
Randomization will be 
performed within 24 
hours following the last 
dose of routine caffein e, 
as long as randomization 
is by 36 weeks + 6 days PMA.  
 
 CHANGED TO: : 
“Randomization will be performed, ideally,  on 
the day following, but no 
later than the third calendar day following, 
the last dose of routine 
caffeine, as long as 
randomization and To allow a 3 -day window after the last dose of routine 
caffeine for randomization and dosing.  
  Page 51 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 dosing is by 36 weeks + 
6 days PMA.    
4.1 STUDY DESIGN 
Overall Design, Multi- Site 
Study  Substitute “multiple” 
for “8”, remove “6” , 
delete all cities and 
states  listed.  We continue to increase the number of participating 
hospitals to help increase enrollment.  
5.1 STUDY 
POPULATION: Inclusion 
Criteria #2  Added Sentence to end 
of criteria #2:. “ Note infants will meet this 
inclusion criteria through 
the third calen dar day 
following receiving their 
most recent routine 
caffeine dose.”  To allow for a window of 3 days after last dose of 
clinical caffeine to be considered “on caffeine”, 
therefore meeting the eligibility requirement.  
5.1 STUDY 
POPULATION: Inclusion 
Criteria #5 Criterion #5 changed 
from: “ Breathing room 
air with no ventilatory 
support for ≥ 12 hours 
and not expected to 
relapse (Note that infants on room air  nasal air 
flow therapy, will NOT  
be considered to be on ventilatory support). “  
 
CHANGED TO : At 
least 12 hours of 
breathing room air  with 
no ventilatory support 
other than on room air  
nasal air flow therapy regardless of flow rate, 
or on room air  and 
receiving nasal CPAP, 
and relapse not 
anticipated.  
 
 
  To increase eligibility to now include infants on 
respiratory support to include nasal air flow therapy 
of any flow rate, or nasal CPAP providing they are 
breathing ROOM AIR with NO SUPPLEMENTAL 
OXYGEN.  
 
Also to be more consistent with evolving changes in 
clinical practice.  
5.5 Recruit ment  2nd bullet, last sentence, 
ADDED:”  If an infant is 
a transfer from another facility at ≤36+6, they 
WILL be added to the 
screening log.  If they are 
a transfer from another 
facility at ≥37+0, they WILL NOT be added to 
the screening log.”  
 To explain screening log protocol for infants 
transferred from other facilities.  
5.5 Recruitment  3rd bullet, 2nd sentence 
deleted:  
“Based on pilot studies, 
it is estimated that Estimati on of pilot study’s consent rate to this study’s 
participation is an inaccurate comparison because of 
COVID’s influence on ability of staff to 
approach/consent  families.  
  Page 52 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 about 30 -35% of 
families approached for 
consent will consent to 
participate.”  
   
8.1.2 Inflammatory 
Biomarkers  2nd paragraph: Remove 
“40 plex V Plex” and 
“(MesoScale 
Diagnostics, Rockville 
MD)  Changes made to reflect newly available  assay 
methods.  
10.1.1.1  CHANGED FROM: The 
Consent Form describing 
in detail the study 
intervention, study 
procedures, and risks will 
be given to the parents of 
each eligible subject. 
Written documentation 
of informed consent will 
be obtained prior to 
enrolling each infant  
 CHANGED TO:  
All informational 
documents and consent 
material to be provided 
to parents of potential 
study subjects wi ll be 
submitted to study site 
IRB’s and utilized in 
accordance with 
procedures approved by the IRB.  
 
DELETED: The Consent 
Form is being submitted with this protocol  
 To allow for various consenting methods approved by 
site-specific  IRBs  
10.1.1.2  Added: ó r their 
designee” to: “the 
investigator will explain 
the research study to 
the parent…”  
 
Removed “written” 
from consent  To allow for investigator -designated study team 
members to explain the study to potential 
participants.  
 
 
 
 
Consent, written or otherwise,  may be obtained per 
IRB requirements.  
10.1.5 Key Roles and Study 
Governance: Study 
Leadership  2nd bullet: CHANGE 
FROM:  There will be a 
Steering Committee , 
chaired in rotating years 
by Drs. Hunt and To condense listings of committees, and to align 
meetings with current standards of virtual meetings.  
  Page 53 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 Eichenwald. Other 
members will be Drs. 
McEnti re (Project 
Director), Corwin (DCC), 
and Darnall, Dobson, 
Fort, Frantz, Hartman, 
Heeren, Limperopoulos, 
Poets, Revenis, Rhein, 
and Stark.  This group will 
be responsible for 
coordinating and 
managing all phases of 
this study. They will meet 
at funding onset  to 
establish responsibilities 
and timelines, complete 
the manual of operations, 
and then meet biweekly 
in Quarter (Q) 1 -2 of Year 
1, and monthly thereafter. 
The committee will meet 
face- to-face initially  and 
once/year ; all other 
meetings will be virtual. 
Y1 will be used to 
complete all project 
materials, train site 
personnel, and obtain 
IRB approvals. 
CHANGE TO:  
There will be a Steering 
Committee , chaired in 
rotating years by Drs. 
Hunt and Eichenwald. 
Other members will be 
Drs. McEntire (Project 
Director),  Corwin (DCC), 
Heeren, Limperopoulos, 
Poets, Darnall and 
Revenis and a 
representative from each 
clinical site. This group 
will be responsible for 
coordinating and 
managing all phases of 
this study 
 
10.1.5 Key Roles and Study 
Governance: Study Leadership  3rdbullet:Change 
FROM: Executive 
Committee  (EC): Drs. 
Hunt and Eichenwald 
(Co-PI), Dr. McEntire 
(Project Director), and 
Dr. Corwin (DCC) will To condense listings of committees, and to align 
meetings with current standards of virtual meetings.  
  Page 54 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 provide overa ll study 
oversight and 
coordination, and 
resolution of any site -
specific issues. The EC 
will meet meet in 
conjunction with SC 
meetings, and will also 
meet virtually as needed, 
biweekly. CHANGE TO: 
Executive Committee  
(EC): Drs. Hunt and 
Eichenwald (Co -PI), Dr. 
McEntire (Project 
Director), and Dr. Corwin 
(DCC) will provide 
overall study oversight 
and coordination, and 
resolution of any site -
specific issues. The EC 
will meet meet virtually 
as needed, generally on a biweekly basis.  
 
 
10.1.11  2nd bullet:  
Added “ PubMed 
Central” after “digital 
archive…”  To specify where the final peer -reviewed journal 
manuscripts will be published.  
CHANGES FROM  PROTOCOL VERSION  4.1 to 4.2  
1.1 Synopsis  Added: P ulse oximeter 
will continue either until 
hospital discharge or for 
1 week after 
discontinuing study 
drug, depending on 
whether the infant was 
recruited at a study site 
at which home oximetry 
recording is being 
performed.  Since home oximetry is challenging for parents, and a 
potential deterrent to enrollment, especially in the 
pandemic environment, we have determined that it 
was appropriate to offer sites the option of not 
participating in the home oximetry , and that overall 
enrollment would enhance our ability to achieve study 
goals, even if the home oximetry data were available 
on only a subset of the infants.  
1.1 Schedule of Activities  Added footnotes 10 and 
11 noting that  Home-
Oximetry and MRIs  
performed for subjects 
enrolled at sites 
participating in  the 
home oximetry and MRI 
portions of the study, 
respectively.  
 To clarify the MRI procedure language related to 
participation  being only in a subset of subjects . 
2.2.1 Known Potential 
Risks, 7th bullet  Added: for those 
participants enrolled at 
sites at which home Since home oximetry is challenging for parents, and a 
potential deterrent to enrollment, especially in the 
pandemic environment, we felt it was appropriate to 
  Page 55 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 oximetry is included in 
the study.  offer sites the option of not participating in the home 
oximetry, and that overall enrollment wou ld enhance 
our ability to achieve study goals, even if the home 
oximetry data were available on only a subset of the 
infants.  
2.2.2 Known Potential 
Benefits : (General future 
potential benefits  to fill 
major gaps in our current 
knowledge ) Added: “ (for participants 
receiving home 
oximetry),” to  benefit #3) 
the frequency and 
severity of IH  persisting 
at home after discharge  Since home oximetry is challenging for parents, and a 
potential deterrent to enrollment, especially in the 
pandemic environment, we felt it was appropriate to 
offer sites the option of not participating in the home 
oximetry, and that overall enrollment would enhance 
our ability to achieve study goals, even if the home 
oximetry data were available on only a subset of the 
infants.  
4.4. End of Study Definition  Added  the BOLDED 
words:  Each subject 
will be considered to 
have completed the study after the planned pulse 
oximeter recording data is completed  and 
inflammatory biomarker 
samples are provided , 
and if applicable , has 
completed the outpatient 
brain MRI between 43 
weeks + 0 days and 46 weeks + 6 days PMA, as 
shown in the Schedule of 
Activities (SOA), Section 1.3.  
 Added language to clarify the MRI procedure and 
oximetry procedure related to participation being for  
only a subset of subjects.  
5.5 Recruitment and 
Retention: (retention)  Added “if applicable” to 
the section on contacting 
families on use of 
oximeter.  Added language to clarify the home -oximetry 
procedure related to participation being only for a 
subset of subjects  
6.5.1 Rescue Medicine  Added: Pulse oximeter 
recordings will continue through hospital 
discharge, or at home 
through 1 week 
following 
discontinuation of study drug, for infants 
recruited at sites participating in home 
oximeter recording . The 
PMA at which study 
drug is scheduled to end 
is well after the clinical team judged it safe to 
stop routine caffeine 
treatment and at a PMA 
at which prior studies 
have shown that the Added language  to clarify the home -oximetry 
procedure related to participation  being only for a 
subset of subjects.  
  Page 56 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 extent of IH no longer 
differs from healthy 
infants born at term. 
However, for sites 
continuing oximeter 
recordings at home, the 
oximeter alarms may be 
activated for this final 
study week if deemed 
necessary by the clinical 
site principal investigators.  
 
8.1.1 Oxygen Saturation  Removed and added 
language : Continuous 
recording of O 2 saturation 
using the study pulse 
oximeter is planned for 
all infants throu gh 
hospital discharge, and 
for the sub -group of 
infants recruited at 
hospitals participating in 
home oximetry recording ,will continue  through 43 
weeks + 6 days PMA (i.e. 
one week following the 
last dose of study drug).   Removed and added language to cla rify the home -
oximetry procedure related to participation being 
only for a subset of subjects.  
8.1.1 Oxygen Saturation: 
Outpatient Phase  Added: At sites, 
participating in the home 
oximetry portion of the 
study, prior  Added language to clarify the home -oximetry 
procedure related to participation being only for a 
subset of subjects.  
8.1.3 QUANTITATIVE 
MRI STRUCTURAL, 
MICROSTRUCTURAL 
AND METABOLIC 
BIOMARKERS OF 
ACUTE BRAIN INJURY  
 Added: “ approximately 
half of the study 
participants” to our goal is to obtain baseline and 
follow -up MRI pairs in:  To clarify the percentage of participating subjects on 
whom we aim to obtain MRI pairs.  
8.1.3 Quantitative MRI 
Structural, Microstructural 
and Metabolic Biomarkers of 
Acute Brain Injury  Added: “At sites 
recruiting infants into the 
MRI portion of the 
study,”  Added language to clarify the MRI procedure related 
to participation being for only a subset of subjects.  
1.1 Synopsis 
OBJECTIVES: “Phase ” Deleted “phase 3”, added 
“not applicable”  Our protocol does not fit the definition of a Phase 3, or 
Phase 2, study  
1.1 Synopsis 
OBJECTIVES, Description of Sites/Facilities Enrolling 
Participants  After “once discharged”, 
Added “if the subject has been enro
lled at a site 
performing MRIs  To clarify the MRI procedure related to participation 
being for only a subset of participants.  
1.1 Synopsis 
OBJECTIVES, Description of Sites/Facilities Enrolling 
Participants  Added “At the end of the 
study, study termination 
procedures will be 
performed in a manner To clarify the end of study  procedur es, may be done 
remotely for the convenience of the family . 
  Page 57 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 convenient for the family, 
and may be performed in 
person or remotely, and if 
applicable may be 
performed at the time of 
an MRI.  
6.2.3  Added “if applicable, or 
sent back”  To clarify that for the convenience of the family, study 
drug may be shipped  back in lieu of an in -person visit.  
1.1 Participant Duration  Added “The end of 
study procedures  
include: return of the 
oximeter  (if 
applicable) , 
salivary  sample and 
any unused study drug .  
As noted above, these 
procedures will done at 
the convenience of the 
family, and although a 
face- to-visit is 
preferred,  all items  
may be shipped back if , 
for any reason, the 
parents prefer not to 
travel to the site.  To clarify that the end -of-study procedures may be done 
in person or remotely for the family’s convenience.  
1.3 Schedule of Activities, 
footnote 8  Added, “which may be 
done remotel y” (referring 
to the end of study visit), 
and added, “Items may be 
shipped back if the 
parents opt for a remote 
visit.  To clarify that end -of-study procedures may be done 
remotely for the parents’ convenience.  
5.5 Retention  3rd bullet:  Added “if 
applicable” to “return 
visit”.  To clarify that end -of-study procedures may be done 
remotely for the parents’ convenience.  
 
 
   
 
  
 
REFERENCES  
1. Henderson -Smart DJ, Steer P. Prophylactic methylxanthine for preventing of apnea in preterm infants. Cochrane 
Database Syst Rev. 2009 2009;2(2000- CD000432):Last review ed 2009.  
  Page 58 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 2. Gray PH, Flenady VJ, Charles BG, Steer PA, Group CCS. Caffeine citrate for very preterm infants: Effects on 
development, temperament and behaviour. Journal of Pa ediatrics and Child Health. 2011 2011;47(4):167- 172.  
3. Steer P, Flenady V, Shearman A, et al. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. Archives of Disease in Childhood -  Fetal and Neonatal Edition. 11/1/ 2004 2004;89(6):F499- F503.  
4. Finer NN, Higgins R, Kattwinkel J, Martin RJ. Summary Proceedings From the Apnea -of-Prematurity Group. 
Pediatrics. 3/1/2006 2006;117(3):S47 -S51.  
5. Ment LR, Scott DT, Ehrenkranz RA, Duncan CC. Early childhood developmental fol low-up of infants with 
GMH/IVH: effect of methylxanthine therapy. Am J Perinatol. 1985 1985;2(3):223 -227.  
6. Davis PG, Schmidt B, Roberts RS, et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. 
The Journal of pediatrics. 2010 2010;156(3):382- 387.  
7. Doyle LW, Cheong J, Hunt RW, et al. Caffeine and brain development in very preterm infants. Annals of neurology. Nov 2010;68(5):734- 742.  
8. Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and 
timing of therapy in very low birth weight infants. The Journal of pediatrics. May 2014;164(5):992 -998 e993.  
9. Davis PG, Schmidt B, Roberts RS, et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. The Journal of pediatrics. Mar 2010;156(3):382- 387.  
10. Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine 
therapy for apnea of prematurity. J AMA . 2012 2012;307(3):275- 282.  
11. Schmidt B, Roberts RS, Davis P, et al. C affeine therapy for apnea of prematurity. The New England journal of 
medicine. May 18 2006;354(20):2112- 2121.  
12. Poets CF, Roberts RS, Schmidt B, et al. Association Between Intermittent Hypoxemia or Bradycardia and Late Death or Disability in Extremely Pr eterm Infants. J AMA . Aug 11 2015;314(6):595- 603.  
13. Bolivar JM, Gerhardt T, Gonzalez A, et al. Mechanisms for episodes of hypoxemia in preterm infants undergoing mechanical ventilation. The Journal of pediatrics. Nov 1995;127(5):767- 773.  
14. Dimaguila MA,  Di Fiore JM, Martin RJ, Miller MJ. Characteristics of hypoxemic episodes in very low birth weight 
infants on ventilatory support. The Journal of pediatrics. Apr 1997;130(4):577- 583.  
15. Hunt CE, Corwin MJ, Lister G, et al. Precursors of cardiorespiratory events in infants detected by home memory 
monitor. Pediatric pulmonology. Jan 2008;43(1):87 -98. 
16. Hunt CE, Corwin MJ, Weese -Mayer DE, et al. Longitudinal assessment of hemoglobin oxygen saturation in 
preterm and term infants in the first six months of li fe. The Journal of pediatrics. Sep 2011;159(3):377 -383 e371.  
17. Poets CF, Stebbens VA, Alexander JR, Arrowsmith WA, Salfield SA, Southall DP. Arterial oxygen saturation in 
preterm infants at discharge from the hospital and six weeks later. The Journal of pediatrics. Mar 1992;120(3):447-
454.  
  Page 59 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 18. Rhein LM, Dobson NR, Darnall RA, et al. Effects of caffeine on intermittent hypoxia in infants born prematurely: 
a randomized clinical trial. JAMA pediatrics. Mar 2014;168(3):250- 257.  
19. Nagata N, Saji M, Ito T, Ikeno S, Takahashi H, Terakawa N. Repetitive intermittent hypoxia- ischemia and brain 
damage in neonatal rats. Brain Dev. Aug 2000;22(5):315- 320.  
20. Douglas RM, Miyasaka N, Takahashi K, Latuszek- Barrantes A, Haddad GG, Hetherington HP. Chronic 
intermittent b ut not constant hypoxia decreases NAA/Cr ratios in neonatal mouse hippocampus and thalamus. 
American journal of physiology. Regulatory, integrative and comparative physiology. Mar 2007;292(3):R1254 -1259.  
21. Neubauer JA. Invited review: Physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol (1985). Apr 2001;90(4):1593- 1599.  
22. Ryan S, McNicholas WT. Inflammatory cardiovascular risk markers in obstructive sleep apnoea syndrome. 
Cardiovasc Hematol Agents Med Chem. 2009 2009;7( 1):76 -81. 
23. Gottlieb DJ, Chase C, Vezina RM, et al. Sleep -disordered breathing symptoms are associated with poorer 
cognitive function in 5- year -old children. The Journal of pediatrics. 10/2004 2004;145(4):458- 464.  
24. Hunt CE. Neurocognitive outcomes in sleep -disordered breathing. The Journal of pediatrics. 10/2004 
2004;145(4):430- 432.  
25. Bass JL, Corwin M, Gozal D, et al. The effect of chronic or intermittent hypoxia on cognition in childhood: a 
review of the evidence. Pediatrics. Sep 2004;114(3):805- 816. 
26. Dammann O, Leviton A. Intermittent or sustained systemic inflammation and the preterm brain. Pediatr Res. 
Mar 2014;75(3):376- 380.  
27. Leviton A, Kuban KC, Allred EN, et al. Early postnatal blood concentrations of inflammation -related proteins 
and microcephaly two years later in infants born before the 28th post -menstrual week. Early Hum Dev. May 
2011;87(5):325- 330.  
28. O'Shea TM, Allred EN, Kuban KC, et al. Elevated concentrations of inflammation -related proteins in postnatal 
blood predict severe d evelopmental delay at 2 years of age in extremely preterm infants. The Journal of pediatrics. 
Mar 2012;160(3):395- 401 e394.  
29. Douglas -Escobar M, Weiss MD. Biomarkers of hypoxic -ischemic encephalopathy in newborns. Front Neurol. 
2012;3:144.  
30. Leviton A,  Allred EN, Dammann O, et al. Systemic inflammation, intraventricular hemorrhage, and white matter 
injury. J Child Neurol. Dec 2013;28(12):1637 -1645.  
31. D'Angio CT, Ambalavanan N, Carlo WA, et al. Blood Cytokine Profiles Associated with Distinct Patterns of 
Bronchopulmonary Dysplasia among Extremely Low Birth Weight Infants. The Journal of pediatrics. Jul 
2016;174:45- 51 e45.  
32. Martin RJ, Wang K, Koroglu O, Di Fiore J, Kc P. Intermittent hypoxic episodes in preterm infants: do they matter? Neonatology. 20 11;100(3):303 -310.  
  Page 60 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 33. Di Fiore JM, Bloom JN, Orge F, et al. A higher incidence of intermittent hypoxemic episodes is associated with 
severe retinopathy of prematurity. The Journal of pediatrics. Jul 2010;157(1):69 -73. 
34. Di Fiore JM, Kaffashi F, Loparo K , et al. The relationship between patterns of intermittent hypoxia and 
retinopathy of prematurity in preterm infants. Pediatr Res. Dec 2012;72(6):606 -612.  
35. Gozal D, Reeves SR, Row BW, Neville JJ, Guo SZ, Lipton AJ. Respiratory Effects of Gestational Int ermittent 
Hypoxia in the Developing Rat. American journal of respiratory and critical care medicine. 6/1/2003 2003;167(11):1540 -1547.  
36. Prabhakar NR. Physiological and Genomic Consequences of Intermittent Hypoxia: Invi ed Review: Oxygen 
sensing during in termittent hypoxia: cellular and molecular mechanisms. Journal of Applied Physiology. 5/1/2001 
2001;90(5):1986- 1994.  
37. Prabhakar NR, Fields RD, Baker T, Fletcher EC. Intermittent hypoxia: cell to system. AJP -  Lung Cellular and 
Molecular Physiology. 9/1/ 2001 2001;281(3):L524 -L528.  
38. Feldman JL, Mitchell GS, Nattie EE. BREATHING: Rhythmicity, Plasticity, Chemosensitivity. Annual Review of 
Neuroscience. 3/1/2003 2003;26(1):239- 266.  
39. Machaalani R, Waters KA. Postnatal nicotine and/or intermittent hypercapnic hypoxia effects on apoptotic markers in the developing piglet brainstem medulla. Neuroscience. 9/29/2006 2006;142(1):107 -117.  
40. Ratner V, Kishkurno SV, Slinko S, Sodunov AA, Polin RA, Ten VS. The contribution of intermittent hypoxemia to late neuro logical handicap in mice with hyperoxia -induced lung injury. Neonatology. 2007 2007;92(1):50 -58. 
41. Kheirandish L, Gozal D, Pequignot JM, Pequignot J, Row BW. Intermittent hypoxia during development induces 
long- term alterations in spatial working memory, monoamines, and dendritic branching in rat frontal cortex. 
Pediatr Res. Sep 2005;58(3):594- 599.  
42. Decker MJ, Hue GE, Caudle WM, Miller GW, Keating GL, Rye DB. Episodic neonatal hypoxia evokes executive dysfunction and regionally specific alterations in markers of dopamine signaling. Neuroscience. 2003;117(2):417-
425.  
43. McCoy JG, Tartar JL, Bebis AC, et al. Experimental sleep fragmentation impairs attentional set -shifting in rats. 
Sleep. 2007 2007;30(1):52 -60. 
44. Aranda JV, Turmen T, Davis J, et al. Ef fect of caffeine on control of breathing in infantile apnea. The Journal of 
pediatrics. 1983 1983;103(6):975- 978.  
45. Back SA, Craig A, Luo NL, et al. Protective effects of caffeine on chronic hypoxia -induced perinatal white matter 
injury. Annals of neurol ogy. 2006 2006;60(6):696 -705.  
46. Bairam A, Carroll JL. Neurotransmitters in carotid body development. Respiratory Physiology &amp; Neurobiology. 11/15/2005 2005;149(1GÇô3):217 -232.  
47. Carter AJ, O'Connor WT, Carter MJ, Ungerstedt U. Caffeine enhances acetylcholine release in the hippocampus 
in vivo by a selective interaction with adenosine A1 receptors. Journal of Pharmacology and Experimental 
Therapeutics. 5/1/1995 1995;273(2):637- 642.  
  Page 61 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 48. Fredholm BB. Adenosine actions and adenosine receptors after 1 we ek treatment with caffeine. Acta Physiol 
Scand. 1982 1982;115(2):283 -286.  
49. Fredholm BB. Adenosine and neuroprotection. Int Rev Neurobiol. 1997 1997;40:259- 280.  
50. Hadfield MG, Milio C. Caffeine and regional brain monoamine utilization in mice. Life Sci . 1989 
1989;45(26):2637 -2644.  
51. Heyman E, Ohlsson A, Heyman Z, Fong K. The effect of aminophylline on the excursions of the diaphragm in 
preterm neonates. A randomized double -blind controlled study. Acta Paediatr Scand. 1991 1991;80(3):308- 315.  
52. Kirch  DG, Taylor TR, Gerhardt GA, Benowitz NL, Stephen C, Wyatt RJ. Effect of chronic caffeine administration 
on monoamine and monoamine metabolite concentrations in rat brain. Neuropharmacology. 1990 
1990;29(6):599- 602.  
53. Mayock DE, Standaert TA, Woodrum DE.  Effect of methylxanthines on diaphragmatic fatigue in the piglet. 
Pediatr Res. 1992 1992;32(5):580- 584.  
54. Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, 
metabolic and psychostimulant effects. Bra in Res Brain Res Rev. 1992 1992;17(2):139 -170.  
55. Rivkees SA, Wendler CC. Adverse and Protective Influences of Adenosine on the Newborn and Embryo: 
Implications for Preterm White Matter Injury and Embryo Protection. Pediatr Res. 4/2011 print 2011;69(4):271 -
278.  
56. Supinski GS, Deal JR EC, Kelsen SG. The effects of caffeine and theophylline on diaphragm contractility. Am Rev 
Respir Dis. 1984 1984;130(3):429- 433.  
57. Supinski GS, Levin S, Kelsen SG. Caffeine effect on respiratory muscle endurance and sense of effort during loaded breathing. J Appl Physiol. 1986 1986;60(6):2040- 2047.  
58. Turner CP, Seli M, Ment L, et al. A1 adenosine receptors mediate hypoxia -induced ventriculomegaly. 
Proceedings of the National Academy of Sciences of the United States of America. 9/30/2003 2003;100(20):11718 -
11722.  
59. Turner CP, Yan H, Schwartz M, Othman T, Rivkees SA. A1 adenosine receptor activation induces ventriculomegaly and white matter loss. Neuroreport. 2002 2002;13(9):1199- 2204.  
60. Wilson CG, Martin RJ, Jaber M, et  al. Adenosine A2A receptors interact with GABAergic pathways to modulate 
respiration in neonatal piglets. Respiratory Physiology &amp; Neurobiology. 7/20/2004 2004;141(2):201- 211.  
61. Kostovic I. Structural and histochemical reorganization of the human pr efrontal cortex during perinatal and 
postnatal life. Prog Brain Res. 1990;85:223- 239; discussion 239- 240.  
62. Kostovic I, Jovanov -Milosevic N. The development of cerebral connections during the first 20 -45 weeks' 
gestation. Semin Fetal Neonatal Med. Dec 20 06;11(6):415- 422.  
63. Volpe JJ. Neuronal proliferation, migration, organization, and myelination. In: Saunders NA, ed. Neurology of the Newborn. 5th ed. Philadelphia, PA: Elsevier; 2009.  
  Page 62 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 64. Kostovic I, Judas M, Rados M, Hrabac P. Laminar organization of t he human fetal cerebrum revealed by 
histochemical markers and magnetic resonance imaging. Cereb Cortex. May 2002;12(5):536- 544.  
65. Volpe JJ, Kinney HC, Jensen FE, Rosenberg PA. The developing oligodendrocyte: key cellular target in brain 
injury in the pre mature infant. International Journal of Developmental Neuroscience. 6/2011 2011;29(4):423 -440.  
66. Ball G, Srinivasan L, Aljabar P, et al. Development of cortical microstructure in the preterm human brain. Proc 
Natl Acad Sci U S A. Jun 4 2013;110(23):9541- 9546.  
67. Engelhardt E, Inder TE, Alexopoulos D, et al. Regional impairments of cortical folding in premature infants. 
Annals of neurology. Jan 2015;77(1):154- 162.  
68. Limperopoulos C, Chilingaryan G, Sullivan N, Guizard N, Robertson RL, du Plessis AJ. Inj ury to the premature 
cerebellum: outcome is related to remote cortical development. Cereb Cortex. Mar 2014;24(3):728- 736.  
69. Rose J, Cahill -Rowley K, Vassar R, et al. Neonatal brain microstructure correlates of neurodevelopment and gait 
in preterm childre n 18 -22 months of age: an MRI and DTI study. Pediatr Res. Aug 31 2015.  
70. Smyser TA, Smyser CD, Rogers CE, Gillespie SK, Inder TE, Neil JJ. Cortical Gray and Adjacent White Matter 
Demonstrate Synchronous Maturation in Very Preterm Infants. Cereb Cortex. J ul 24 2015.  
71. Zacharia A, Zimine S, Lovblad KO, et al. Early assessment of brain maturation by MR imaging segmentation in neonates and premature infants. AJNR Am J Neuroradiol. May 2006;27(5):972 -977.  
72. Back SA. Brain Injury in the Preterm Infant: New Horizons for Pathogenesis and Prevention. Pediatric 
neurology. Sep 2015;53(3):185- 192.  
73. Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC. Late Oligodendrocyte Progenitors Coincide 
with the Developmental Window of Vulnerability for Human Pe rinatal White Matter Injury. The Journal of 
Neuroscience. 2/15/2001 2001;21(4):1302 -1312.  
74. Morag I, Okrent AL, Strauss T, et al. Early neonatal morbidities and associated modifiable and non -modifiable 
risk factors in a cohort of infants born at 34 -35 we eks of gestation. J Matern Fetal Neonatal Med. May 
2015;28(8):876- 882.  
75. Kinney HC. The Near -Term (Late Preterm) Human Brain and Risk for Periventricular Leukomalacia: A Review. 
Seminars in Perinatology. 4/2006 2006;30(2):81- 88. 
76. Aarnoudse -Moens CSH, Weisglas -Kuperus N, van Goudoever JB, Oosterlaan J. Meta -Analysis of 
Neurobehavioral Outcomes in Very Preterm and/or Very Low Birth Weight Children. Pediatrics. 8/1/2009 
2009;124(2):717- 728.  
77. Dahl LB, Kaaresen PI, Tunby J, Handegard BH, Kvernmo S, Ronni ng JA. Emotional, Behavioral, Social, and 
Academic Outcomes in Adolescents Born With Very Low Birth Weight. Pediatrics. 8/1/2006 2006;118(2):e449 -
e459.  
78. Fily A, Pierrat V, Delporte V, Breart G, Truffert P, Group EN -P-d-CS. Factors associated with 
neurodevelopmental outcome at 2 years after very preterm birth: the population -based Nord- Pas-de-Calais 
EPIPAGE cohort. Pediatrics. Feb 2006;117(2):357 -366.  
  Page 63 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 79. Hack M, Taylor HG, Drotar D, et al. Chronic Conditions, Functional Limitations, and Special Health Ca re Needs of 
School -aged Children Born With Extremely Low -Birth -Weight in the 1990s. JAMA: The Journal of the American 
Medical Association. 7/20/2005 2005;294(3):318 -325.  
80. Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD, Network ftNIoCHaHDNR. Change s in 
Neurodevelopmental Outcomes at 18 to 22 Months' Corrected Age Among Infants of Less Than 25 Weeks' 
Gestational Age Born in 1993- 1999. Pediatrics. 6/1/2005 2005;115(6):1645- 1651.  
81. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Manacker F, Kirmeyer S. Births: final data for 2004. Vol 55. 1 ed. Hyattsville, MD: National Center for Health Statistics; 2006.  
82. Moreira RS, Magalhaes LC, Alves CR. Effect of preterm birth on motor development, behavior, and school performance of school -age children: a syst ematic review. J Pediatr (Rio J). Mar -Apr 2014;90(2):119 -134.  
83. Peacock JL, Marston L, Marlow N, Calvert SA, Greenough A. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr Res. Mar 2012;71(3):305 -310.  
84. Vincer MJ, Allen AC, J oseph KS, Stinson DA, Scott H, Wood E. Increasing Prevalence of Cerebral Palsy Among 
Very Preterm Infants: A Population -Based Study. Pediatrics. 12/1/2006 2006;118(6):e1621- e1626.  
85. Back SA, Luo NL, BORENSTEIN NS, Volpe JJ, Kinney HC. Arrested Oligodendrocyte Lineage Progression During 
Human Cerebral White Matter Development: Dissociation Between the Timing of Progenitor Differentiation and 
Myelinogenesis. Journal of Neuropathology & Experimental Neurology. 2002 2002;61(2).  
86. Julien CA, Joseph  V, Bairam A. Caffeine reduces apnea frequency and enhances ventilatory long -term 
facilitation in rat pups raised in chronic intermittent hypoxia. Pediatr Res. 2010 2010;68(2):105- 111.  
87. Kinney HC, Haynes RL, Xu G, et al. Neuron deficit in the white matt er and subplate in periventricular 
leukomalacia. Annals of neurology. 2012 2012;71(3):397 -406.  
88. Schmidt B, Roberts RS, Davis P, et al. Long -Term Effects of Caffeine Therapy for Apnea of Prematurity. The New 
England journal of medicine. 11/8/2007 2007;357(19):1893 -1902.  
89. Dobson NR, Liu X, Rhein LM, et al. Salivary caffeine concentrations are comparable to plasma concentrations in 
preterm infants receiving extended caffeine therapy. British journal of clinical pharmacology. Sep 2016;82(3):754-
761.  
90. Dobson N, Rhein L, Corwin MJ, Darnall R, Heeren T, McEntire B, Rybin D, Hunt  CE. Intermittent hypoxia and 
caffeine pharmacokinetics in preterm infants. J Perinatology 2017;37:1135- 1140; published online July 27, 2017.  
91. Juliano C, Sosunov S, Niatsetskaya Z, et al. Mild intermittent hypoxemia in neonatal mice causes permanent 
neurofunctional deficit and white matter hypomyelination. Experimental neurology. Feb 2015;264:33- 42. 
92. Shams I, Avivi A, Nevo E. Hypoxic stress tolerance of the blind subterranean m ole rat: expression of 
erythropoietin and hypoxia -inducible factor 1 alpha. Proc Natl Acad Sci U S A. Jun 29 2004;101(26):9698- 9703.  
93. Raman L, Tkac I, Ennis K, Georgieff MK, Gruetter R, Rao R. In vivo effect of chronic hypoxia on the 
neurochemical profi le of the developing rat hippocampus. Brain research. Developmental brain research. May 12 
2005;156(2):202- 209.  
  Page 64 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 94. Xia Y, Fu Y, Xu H, Guan J, Yi H, Yin S. Changes in cerebral metabolites in obstructive sleep apnea: a systemic 
review and meta -analysis. Sci entific reports. Jun 28 2016;6:28712.  
95. Alkan A, Sharifov R, Akkoyunlu ME, et al. MR spectroscopy features of brain in patients with mild and severe obstructive sleep apnea syndrome. Clinical imaging. Nov -Dec 2013;37(6):989- 992.  
96. Julien CA, Niane L, K inkead R, Bairam A, Joseph V. Carotid sinus nerve stimulation, but not intermittent 
hypoxia, induces respiratory LTF in adult rats exposed to neonatal intermittent hypoxia. American journal of physiology. Regulatory, integrative and comparative physiology.  Jul 2010;299(1):R192 -205.  
97. Gholipour A, Limperopoulos C, Clancy S, et al. Construction of a deformable spatiotemporal MRI atlas of the 
fetal brain: evaluation of similarity metrics and deformation models. Med Image Comput Comput Assist Interv. 
2014;17( Pt 2):292 -299.  
98. Clouchoux C, Guizard N, Evans AC, du Plessis AJ, Limperopoulos C. Normative fetal brain growth by quantitative in vivo magnetic resonance imaging. Am J Obstet Gynecol. Feb 2012;206(2):173 e171 -178.  
99. Andescavage N DA, McCarter R, Seraq  A, Vezina G, Evangelou I, Robertson R, Limperopoulos C. Complex 
trajectories of brain development in the healthy human fetus. Cerebral Cortex. 2016 (in press).  
100  Clouchoux C, Kudelski D, Gholipour A, et al. Quantitative in vivo MRI measurement of corti cal development in 
the fetus. Brain Struct Funct. Jan 2012;217(1):127 -139.  
101. Bouyssi -Kobar M DA, McCarter R, Brossard -Racine M, Murnick J, Tinkleman L, Robertson R, Limperopoulos C. 
Third Trimester Brain Growth in Preterm Infants compared with In Utero Healthy Fetuses. Pediatrics. 2016 (in press).  
102. Evangelou IE, Serag A, Bouyssi -Kobar M, Plessis AJ, Limperopoulos C. Optimized methodology for neonatal 
diffusion tensor imaging processing and study- specific template construction. Conf Proc IEEE Eng Med Biol Soc. 
2014;2014:2372 -2375.  
103. Ramanathan R, Corwin MJ, Hunt CE, et al. Cardiorespiratory Events Recorded on Home Monitors: Comparison 
of Healthy Infants With Those at Increased Risk for SIDS. JAMA: The Journal of the American Medical Association. 
5/2/2001 2001;285(17):2199- 2207.  
104. Brockmann PE, Poets A, Urschitz MS, Sokollik C, Poets CF. Reference values for pulse oximetry recordings in 
healthy term neonates. Archives of disease in childhood. Fetal and neonatal edition. 2011 2011;[Epub ahead of 
print]. 
105. Urschitz MS, Von EV, Seyfang A, Poets CF. Use of pulse oximetry in automated oxygen delivery to ventilated 
infants. Anesthesia and analgesia. Jan 2002;94(1 Suppl):S37 -40. 
106. Lee TC, Charles BG, Steer PA, Flenady VJ. Saliva as a Valid Alternativ e to Serum in Monitoring Intravenous 
Caffeine Treatment for Apnea of Prematurity. [Article]. Therapeutic Drug Monitoring. 6/1996 1996;18(3):288 -293.  
107. Perera V, Gross AS, McLachlan AJ. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment  
using saliva and plasma. Biomedical Chromatography. 2010 2010;24(10):1136 -1144.  
  Page 65 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 108. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition 
of bronchopulmonary dysplasia. Pediatrics. Dec 2005;116(6):1353- 1360.  
109. Carlo WA, McDonald SA, Tyson JE, et al. Cytokines and neurodevelopmental outcomes in extremely low birth weight infants. The Journal of pediatrics. Dec 2011;159(6):919- 925 e913.  
110. Kuban KC, O'Shea TM, Allred EN, et al. The breadth and type of systemic inflammation and the risk of adverse 
neurological outcomes in extremely low gestation newborns. Pediatric neurology. Jan 2015;52(1):42- 48. 
111. Skogstrand K, Ekelund CK, Thorsen P, et al. Effects of blood sample handling procedures on measura ble 
inflammatory markers in plasma, serum and dried blood spot samples. J Immunol Methods. Jul 20 2008;336(1):78 -
84. 
112. Ambalavanan N, Carlo WA, D'Angio CT, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weigh t infants. Pediatrics. Apr 2009;123(4):1132- 1141.  
113. Kumar R, Chavez AS, Macey PM, Woo MA, Yan -Go FL, Harper RM. Altered global and regional brain mean 
diffusivity in patients with obstructive sleep apnea. J Neurosci Res. Oct 2012;90(10):2043- 2052.  
114. Macey PM, Kumar R, Woo MA, Valladares EM, Yan -Go FL, Harper RM. Brain structural changes in obstructive 
sleep apnea. Sleep. Jul 2008;31(7):967 -977.  
115. Massaro AN, Evangelou I, Fatemi A, et al. White matter tract integrity and developmental outcome in 
newborn infants with hypoxic -ischemic encephalopathy treated with hypothermia. Dev Med Child Neurol. May 
2015;57(5):441- 448.  
116. Massaro AN, Evangelou I, Brown J, et al. Neonatal neurobehavior after therapeutic hypothermia for hypoxic 
ischemic encephalopathy. Early Hum Dev. Oct 2015;91(10):593- 599.  
117. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. Dec 1993;30(6):672- 679.  
118. Longo R, Bampo A, Vidimari R, Magnaldi S, Giorgini A. Absolute qua ntitation of brain 1H nuclear magnetic 
resonance spectra. Comparison of different approaches. Invest Radiol. Apr 1995;30(4):199- 203.  
119. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron -Demilly D. Cramer -Rao bounds: an evaluation tool 
for quantitat ion. NMR Biomed. Jun 2001;14(4):278 -283.  
120. Limperopoulos C, Chilingaryan G, Guizard N, Robertson RL, Du Plessis AJ. Cerebellar injury in the premature infant is associated with impaired growth of specific cerebral regions. Pediatr Res. Aug 2010;68(2):145 -150.  
121. Limperopoulos C, Soul JS, Gauvreau K, et al. Late gestation cerebellar growth is rapid and impeded by 
premature birth. Pediatrics. Mar 2005;115(3):688- 695.  
122. Limperopoulos C, Soul JS, Haidar H, et al. Impaired trophic interactions between th e cerebellum and the 
cerebrum among preterm infants. Pediatrics. Oct 2005;116(4):844- 850.  
  Page 66 of 66 
 
 ICAF Protocol Version 4.2: 27  September 9, 2021  
  
 
 123. Charles, BG, et al. Caffeine Citrate Treatment for Extremely Premature Infants With Apnea: Population 
Pharmacokinetics, Absolute Bioavailability, and Implications for  Therapeutic Drug Monitoring . Neonatal Caffeine 
Population Pharmacokinetics . Dec 2008; 30(6); 709- 716.  
 
 
 